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ABSTRACT OF DISSERTATION 
 
 
 
DEVELOPMENT OF A ROBUST TREATMENT DELIVERY FRAMEWORK FOR 
STEREOTACTIC BODY RADIOTHERAPY (SBRT) OF SYNCHRONOUS 
MULTIPLE LUNG LESIONS 
 
Stereotactic body radiation therapy (SBRT) of lung tumors uses high doses of 
radiation to deliver high biological effective doses (BED) in very few fractions (1-5). 
With the use of highly conformal fields to cover the tumor without depositing large doses 
to non-cancerous structures, this technique has proven time and again to be successful at 
achieving high local control. However, frequently patients receiving SBRT are elderly 
with multiple medical comorbidities who may not tolerate long treatment times. 
Furthermore, many patients present with oligometastatic or multiple primary lung tumors. 
The success of SBRT on oligometastatic lung disease relies on physician experience with 
precise patient positioning and immobilization, not available in all clinics. Likewise, 
there is no standard framework to guide radiation oncology clinics experienced in SBRT 
with planning and treating multiple lung tumors synchronously. This dissertation 
explores the treatment planning methods available for the SBRT of multiple lung lesions 
and presents innovative solutions to the challenges in current practice.  
To begin, two treatment planning methods for multiple lesion SBRT are 
compared: treating each lesion individually with separate isocenters and treating all 
lesions at the same time with a single isocenter. Treating multiple lesions with multiple 
isocenters will increase the patient’s imaging and treatment time and the number of 
instances a radiation therapist must enter the treatment room, thus increasing the chances 
a patient will move from the setup position. Using an individual isocenter placed between 
the tumors and volumetric arc therapy (VMAT) to treat all tumors at the same time can 
reduce the treatment time, increasing patient comfort and decreasing the chance of 
movement from the treatment position. However, there is a chance of decreased target 
coverage and reduced BED due to small setup errors in the SBRT of synchronous lesions 
using a single-isocenter. The dissertation continues by quantifying this loss in target 
coverage using a novel simulation method. Simulations yielded average deviations of 
27.4% (up to 72% loss) (p < 0.001) from planned target coverage. The largest deviations 
from planned coverage and desired BED were seen for the smallest targets (<10 cc), 
some of which received <100 Gy BED, which is suboptimal for SBRT. Patient 
misalignment resulted in a substantial decrease in conformity and increase in the gradient 
index, violating major characteristics of SBRT. To minimize coverage loss due to small 
setup errors, a novel Restricted Single-Isocenter Stereotactic Body Radiotherapy 
     
 
(RESIST) treatment method was developed to provide efficient and effective treatments 
without substantially increasing treatment time. Lastly, RESIST was automated in the 
treatment planning system to allow for efficient and accurate treatment planning for two 
lung lesion SBRT. Automation includes beam geometry, algorithm selection, and an in-
house trained dose volume histogram estimation model to improve plan quality. 
Automated planning significantly improves treatment planning time and decreases the 
chance of planning errors. This treatment delivery framework allows all patients who are 
to be treated with SBRT to multiple lung lesions to be treated efficiently and effectively. 
Further development of RESIST for >2 lesions and multi-site SBRT merits further 
investigation. 
 
KEYWORDS: Lung SBRT, VMAT, Synchronous Multiple Lesions, Setup Errors, 
RESIST, Automation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lana Catherine Critchfield 
(Name of Student) 
 
11/11/2020 
            Date 
 
 
 
 
 
 
 
 
 
 
 
DEVELOPMENT OF A ROBUST TREATMENT DELIVERY FRAMEWORK FOR 
STEREOTACTIC BODY RADIOTHERAPY (SBRT) OF SYNCHRONOUS 
MULTIPLE LUNG LESIONS 
 
 
By 
Lana Catherine Critchfield 
 
 
 
 
 
 
 
 
 
 
 
 
Damodar Pokhrel, PhD, DABR 
Director of Dissertation 
 
Lee Johnson, PhD, DABR 
Director of Graduate Studies 
 
11/11/2020 
Date
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEDICATION 
 
To my husband, Corey, for his endless love and support and to our dog, Nala, for being 
the best pandemic support partner.
iii 
 
ACKNOWLEDGMENTS 
 
I have been a part of the University of Kentucky Department of Radiation 
Oncology since I began graduate school in 2015 as a Master’s student in Medical Physics. 
Although my position has changed over the years, I have always received guidance and 
support from every faculty and staff member. I would not be possible for me to complete 
this dissertation without the help of everyone in the department.  
I am fortunate that I was given the opportunity by Dr. Janelle Molloy and Dr. 
Marcus Randall to complete my PhD here at UK. With the program being new, I am 
honored that they have trusted me to represent the department as one of their first graduates 
from the PhD program. I would like to thank my mentor, Dr. Damodar Pokhrel, for his 
knowledge and dedication. He has provided outstanding commitment to this project and 
has taught me many skills, both clinically and academically.  
I would like to thank Dr. Ronald McGarry for his expertise on the dissertation 
subject matter and for allowing techniques presented in this dissertation to be used in his 
clinical practice. Appreciations to the other members of my committee, Dr. Mark Lovell 
and Dr. Jie Zhang. They have been patient and helpful while we figure out this new 
program. I would also like to acknowledge Dr. Steven Yates who has graciously agreed 
to be the outside examiner for my final examination.  
I would like to express my gratitude to Dr. Mark Bernard for collaborating with 
us throughout this process. Likewise, I would not have gotten here without my fellow PhD 
students Justin Visak and Allison Palmiero who have kept me sane. Lastly, I would like 
to acknowledge Dr. Lee Johnson for teaching me almost everything I know about medical 
iv 
 
physics, for guiding me through the graduate school processes, and for taking time to help 
me solve virtually any problem. 
 
v 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS ................................................................................................. iii 
LIST OF TABLES ........................................................................................................... viii 
LIST OF FIGURES ............................................................................................................ x 
CHAPTER 1. INTRODUCTION ....................................................................................... 1 
1.1 A Brief History of Lung SBRT ................................................................................. 1 
1.2 Multiple Lesion Lung SBRT .................................................................................... 5 
1.3 Purpose of Dissertation .......................................................................................... 7 
1.4 Thesis Organization and Clinical Innovations ....................................................... 7 
CHAPTER 2. EVALUATION OF PLAN QUALITY AND TREATMENT 
EFFICIENCY FOR SINGLE-ISOCENTER/TWO-LESIONS LUNG STEREOTACTIC 
BODY RADIATION THERAPY..................................................................................... 12 
2.1 Introduction........................................................................................................... 13 
2.2 Materials and Methods ......................................................................................... 16 
   2.2.1 Patient setup and Target Delineation ................................................................ 16 
   2.2.2 Treatment Planning ........................................................................................... 17 
2.2.2.1 Clinical Single-Isocenter VMAT Plan .................................................. 17 
2.2.2.2 Two-Isocenter VMAT Plan .................................................................. 18 
   2.2.3 Plan Evaluation ................................................................................................. 19 
   2.2.4 Dose to Other OARs ......................................................................................... 20 
   2.2.5 Delivery Efficiency and Accuracy .................................................................... 20 
2.3 Results ................................................................................................................... 21 
   2.3.1 Target Coverage and Normal Lung Dose ......................................................... 21 
   2.3.2 Dose to Other OARs ......................................................................................... 29 
   2.3.3 Delivery Efficiency and Accuracy .................................................................... 31 
2.4 Discussion ............................................................................................................. 33 
2.5 Conclusion ............................................................................................................ 37 
CHAPTER 3. RISK OF TARGET COVERAGE LOSS FOR STEREOTACTIC BODY 
RADIOTHERAPY TREATMENT OF SYNCHRONOUS MULTIPLE LUNG LESIONS 
VIA SINGLE-ISOCENTER VOLUMETRIC MODULATED ARC THERAPY ........... 38 
3.1 Introduction........................................................................................................... 39 
3.2 Materials and Methods ......................................................................................... 41 
   3.2.1 Patient Setup and Contouring ........................................................................... 41 
   3.2.2 Clinical Single-Isocenter VMAT Plans ............................................................ 43 
vi 
 
   3.2.3 Simulated Single-Isocenter VMAT Plans ......................................................... 43 
   3.2.4 Plan Comparison ............................................................................................... 46 
   3.2.5 Statistical Analysis ............................................................................................ 47 
3.3 Results ................................................................................................................... 47 
3.4 Discussion ............................................................................................................. 55 
3.5 Conclusion ............................................................................................................ 59 
CHAPTER 4. ......... A NOVEL RESTRICTED SINGLE-ISOCENTER STEREOTACTIC 
BODY RADIOTHERAPY (RESIST) METHOD FOR SYNCHRONOUS MULTIPLE 
LUNG LESIONS TO MINIMIZE SETUP UNCERTAINTIES ...................................... 61 
4.1 Introduction........................................................................................................... 62 
4.2 Materials and Methods ......................................................................................... 64 
   4.2.1 Patient Setup and Target Delineation ............................................................... 64 
   4.2.2 Clinical VMAT Plans ....................................................................................... 65 
   4.2.3 RESIST VMAT Plans ....................................................................................... 66 
   4.2.4 Plan Comparison and Data Analysis................................................................. 68 
4.3 Results ................................................................................................................... 69 
   4.3.1 Target Coverage and Dose to OAR .................................................................. 69 
   4.3.2 Treatment Delivery Parameters ........................................................................ 74 
4.4 Discussion ............................................................................................................. 75 
4.5 Conclusion ............................................................................................................ 79 
CHAPTER 5. ........ AUTOMATION AND INTEGRATION OF RESTRICTED SINGLE-
ISOCENTER STEREOTACTIC BODY RADIOTHERAPY (RESIST) METHOD FOR 
SYNCHRONOUS MULTIPLE LUNG LESIONS .......................................................... 81 
5.1 Introduction........................................................................................................... 82 
5.2 Materials and Methods ......................................................................................... 83 
   5.2.1 CT Simulation and Contouring ......................................................................... 84 
   5.2.2 Clinical VMAT Plans ....................................................................................... 85 
   5.2.3 m-RESIST VMAT Plans................................................................................... 86 
   5.2.4 a-RESIST VMAT Plans ................................................................................... 87 
   5.2.5 Plan Comparison and Data Analysis................................................................. 89 
5.3 Results ................................................................................................................... 90 
   5.3.1 Target Coverage and Dose to OAR .................................................................. 90 
   5.3.2 Treatment Planning Parameters ........................................................................ 96 
   5.3.3 Treatment Delivery Parameters ........................................................................ 96 
5.4 Discussion ............................................................................................................. 97 
5.5 Conclusion .......................................................................................................... 100 
CHAPTER 6. STUDY CONCLUSIONS ....................................................................... 101 
6.1 Study Summary.................................................................................................... 101 
vii 
 
6.2 Study Limitations and Future Perspectives ........................................................ 104 
APPENDICES ................................................................................................................ 108 
APPENDIX 1. GLOSSARY ......................................................................................... 108 
APPENDIX 2. MATLAB SCRIPT FOR SIMULATION OF RANDOM SETUP ERRORS
..................................................................................................................................... 110 
APPENDIX 3. ESAPI SCRIPT FOR a-RESIST .......................................................... 112 
REFERENCES ............................................................................................................... 118 
VITA ............................................................................................................................... 130 
viii 
 
 
LIST OF TABLES 
Table 2.1: Comparison of plan evaluation parameters for single-isocenter vs two-isocenter 
treatment plans of all eight lung SBRT patients. .............................................................. 24 
Table 2.2: Normal lung doses statistics between single-isocenter and two-isocenter plans 
for all 8 lung SBRT patients. Data is presented as mean ± standard deviation (range) and 
p-values. ............................................................................................................................ 28 
Table 2.3: Average values of absolute dose differences between single-isocenter and two-
isocenter plans for parameters of the OARs for all 8 lung SBRT patients. Ratio=single-
isocenter/two-isocenter. .................................................................................................... 30 
Table 2.4: The detailed information on total number of MUs and beam-on time for the both 
single-isocenter and two-isocenter plans for all 8 lung SBRT patients. The Octavius 
VMAT-SBRT QA pass rates and point dose measurements for single-isocenter plans were 
also shown. ........................................................................................................................ 32 
Table 3.1: Main tumor characteristics of the 26 lung SBRT patients included in this study. 
Each patient had 2 tumors. STD = standard deviation...................................................... 42 
Table 3.2: Analysis of the dosimetric and delivery parameters for 26 lung SBRT patients 
treated with a single-isocenter/multiple-target VMAT plan. Mean ± STD (range) and p-
values were reported for clinical VMAT and simulated plans. n. s. = not significant. 
Significant values are highlighted in bold. STD = standard deviation. PCN = Paddick 
Conformation Number. ..................................................................................................... 49 
Table 3.3: Analysis of the maximal dose to OAR for 26 lung SBRT patients. Mean ± STD 
(range) and p-values were reported for clinical VMAT and simulated VMAT plans. n. s. = 
not significant. Significant values are highlighted in bold. STD = standard deviation. ... 53 
Table 4.1: Main tumor characteristics of the 21 lung SBRT patients included in this study. 
Each patient had 2 tumors. STD = standard deviation...................................................... 65 
Table 4.2: Analysis of the target coverage of the dosimetric parameters for all 21 lung 
SBRT patients treated with single-isocenter/multiple-lesions VMAT compared to RESIST 
plans. Mean ± STD (range) and p-values were reported. Significant values are highlighted 
in bold. STD = standard deviation. PCN = Paddick Conformation Number. CI = conformity 
index. HI = heterogeneity index........................................................................................ 70 
Table 4.3: Evaluation of dose to OAR for all 21 multi-lesions lung SBRT patients for both 
plans. Mean ± SD (range) was reported. SD = standard deviation. MLD = mean lung dose. 
Statistically significant p-values are highlighted in bold. ................................................. 71 
Table 4.4: Comparison of average values of treatment delivery parameters (and range) 
between clinical VMAT and RESIST plans for all 21 lung SBRT patients. Mean ± SD 
(range) was reported. SD = standard deviation. Statistically significant p-values are 
highlighted in bold. ........................................................................................................... 75 
Table 5.1: Main tumor characteristics of the 10 lung SBRT patients included in this study. 
Each patient had 2 tumors. STD = standard deviation...................................................... 85 
ix 
 
Table 5.2: Analysis of the target coverage of the dosimetric parameters for 10 lung SBRT 
patients. Mean ± STD (range). STD = standard deviation. PCN = Paddick Conformation 
Number. CI = conformity index. HI = heterogeneity index. n = number of targets. ........ 91 
Table 5.3: Comparison of average values of treatment delivery parameters (and range) 
between clinical VMAT, m-RESIST and a-RESIST plans for all 10 lung SBRT patients. 
Mean ± SD (range) was reported. SD = standard deviation. ............................................ 97 
 
 
 
 
x 
 
 
LIST OF FIGURES 
Figure 2.1: The dose volume histogram comparison for the target coverage of Patient #8 
(for both PTV1 and PTV2). .............................................................................................. 22 
Figure 2.2: Comparison of isodose distributions in sagittal view for patient #8 generated 
via single-isocenter and two-isocenter plans. ................................................................... 23 
Figure 2.3: For all 8 lung SBRT patients, the ratios of V5, V10 and V20 of normal lung 
doses calculated by single-isocenter and two-isocenter plans as a function of isocenter to 
tumors distance. ................................................................................................................ 29 
Figure 3.1: The workflow describes the steps required to complete simulation of isocenter 
misalignment in Eclipse TPS in all six dimensions. ......................................................... 45 
Figure 3.2: A demonstration of randomly rotated (within, ± 2°) and translated (within, ± 5 
mm) CT data set (see bottom right inset) around the plan isocenter location (cross-hair) for 
a representative patient (one fraction)............................................................................... 45 
Figure 3.3: Loss of target coverage for all 52 lesions plotted as a function of PTV size. 50 
Figure 3.4: Loss of target coverage for all 52 lesions as a function of binned PTV sizes. 51 
Figure 3.5: Scatter plot of relative dose error for all 52 lesions as a function of distance to 
isocenter. ........................................................................................................................... 51 
Figure 3.6: Comparison of calculated BED10 for both PTV and GTV for all 52 targets is 
shown for both plans. ........................................................................................................ 52 
Figure 3.7: Example dose distribution for Clinical VMAT vs. Simulated VMAT. ......... 54 
Figure 3.8: Dose volume histogram for the example patient. ........................................... 54 
Figure 4.1: The proposed RESIST treatment planning workflow for single-
isocenter/multiple-lesions lung SBRT. ............................................................................. 67 
Figure 4.2: Coronal view for an example clinical plan (left panel) and the RESIST plan 
sum (right panel), each lesion was treated for 50 Gy in 5 fractions synchronously. ........ 72 
Figure 4.3: Axial view for the same example patient. ...................................................... 73 
Figure 4.4: This is an example case of two lesions near one another. .............................. 74 
Figure 4.5: The proposed RESIST treatment delivery workflow for single-
isocenter/multiple-lesions VMAT lung SBRT. ................................................................ 78 
Figure 5.1: The a-RESIST treatment planning workflow for a single-isocenter/two lesions 
VMAT lung SBRT. ........................................................................................................... 89 
Figure 5.2: The pairwise differences between clinical VMAT and a-RESIST plans and 
clinical VMAT and m-RESIST for maximum (left panel) and volumetric (right panel) 
doses to OAR. The stars represent outlier data points. ..................................................... 92 
Figure 5.3: Coronal beam geometry and dose color wash for clinical VMAT, m-RESIST 
and a-RESIST plans. ......................................................................................................... 94 
Figure 5.4: Dose color wash in the axial plan of a patient with bi-lateral lesions. ........... 95 
xi 
 
Figure 5.5: The a-RESIST treatment delivery workflow for single-isocenter/two-lesion 
VMAT lung SBRT. ........................................................................................................... 98 
1 
 
 
CHAPTER 1. INTRODUCTION 
1.1  A Brief History of Lung SBRT 
The eventual concept of stereotactic body radiation therapy (SBRT) originated with 
Lax, Blomgren, and colleagues in 1994 at the Karolinska Hospital in Sweden.1 Their goal 
was to create very precise and accurate treatments for lesions that could not be resected 
and did not respond well to low doses of radiation. Although they focused on abdominal 
malignancies, the technique was inspired by radiosurgery of intracranial targets using a 
Gamma Knife (Elekta, Stockholm, Sweden). Gamma Knife radiosurgery uses a rigid 
stereotactic system attached to the skull for target localization and patient setup. The 
technique uses a high dose with a heterogeneous distribution and is typically delivered in 
a single fraction. Tumor dose is prescribed to the tumor margin (i.e. tumor periphery), 
typically the 50% isodose line. For example, if the dose at the margin is 20 Gy to the 50% 
line, then the maximum dose in the tumor is 40 Gy. Conformation of dose to the target and 
rapid fall-off of dose is required for stereotactic procedures to limit doses to non-cancerous 
structures. The authors took these ideas to create a treatment regimen for extracranial 
lesions. They began with the creation of a stereotactic body frame. The frame consisted of 
a box-like structure with rigid walls on either side of the patient attached to a flat base. The 
walls had position indicators that can be visualized on a CT scan in order to localize the 
tumor. The patient was immobilized on a vacuum pillow and diaphragmatic movements 
were reduced with the use of abdominal compression. Their stereotactic treatments were 
prescribed to a high dose (≥6 Gy/fraction) and delivered in a few fractions, compared to 
conventional fractionation at a dose of 1.8-2 Gy per day for multiple weeks. These plans 
consisted of 6 or 21 MV photons utilizing 4-8 non-coplanar static beams all focused at an 
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isocenter located in the tumor. These planning parameters were dramatically different from 
Gamma Knife planning which used 201 Co-60 beams of 1.25 MV photons. In 1995, the 
same group published the results from the first trial of 31 patients treated with the 
technique.2 This trial included intrahepatic tumors, liver metastases, metastases to the 
thoracic cavity and retroperitoneal and skeletal metastases. The dose was prescribed to the 
margin and planned such that the maximum dose in the target was 50% higher than the 
margin. The maximum doses in the target varied from 9-82 Gy, delivered in 1-4 fractions. 
Observed with patient follow-up, 50% of the irradiated tumors decreased in size and 80% 
had local rate of no progressive disease. Based on these findings, they determined that their 
stereotactic radiotherapy technique was convenient for patients and may be of clinical 
value for extracranial lesions.  
 Focusing on the American progression of SBRT, in 2002 surgery was still 
considered standard primary care for stage 1 non-small cell lung cancer (NSCLC). At the 
VA Medical Center in Indianapolis, Indiana, McGarry and colleagues identified a cohort 
of patients from the institutional tumor registry with NSCLC who were ineligible for 
surgery and thus were left under observation.3 They determined that more than 50% of 
these observation-only patients would die of their lung cancer. Looking to find an 
acceptable treatment option for these patients, they began the first dose escalation trial to 
treat surgically ineligible patients with high doses of radiation in a few fractions. Thus, in 
2003, the institution reported the results from a dose escalation trial utilizing stereotactic 
radiosurgery, called Extracranial Stereotactic Radioablation (ESR), for medically 
inoperable stage 1 NSCLC.4 Prescribed doses escalated from 8 Gy per fraction to 20 Gy 
per fraction in 2 Gy increments. Heterogeneous dose distributions were calculated to water, 
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prescribed such that the tumor margin was covered by the 80% isodose line and delivered 
in 3 fractions over 2 weeks. 87% of tumors responded to the treatment. In all cases of local 
failure, the patient received less than 18 Gy per fraction. This study was just the beginning 
of many to determine the roll of SBRT in the treatment of lung cancer between 2003 and 
2009.5-7 These studies included the first Radiation Therapy Oncology Group (RTOG) 
studies for lung SBRT, RTOG 0236 to study the role of SBRT for patients with medically 
inoperable early stage NSCLC and RTOG 0618 for patients with operable early stage 
NSCLC.8,9 Both studies employed the dosing scheme of 20 Gy per fraction for 3 fractions. 
Similar to the Indiana dose escalation trial, tissue heterogeneities in the lung were not 
considered in the dose calculation. It was observed that 20 Gy without heterogeneity 
correction is roughly equivalent to 18 Gy with corrections. Findings from the studies 
revealed that SBRT to early stage NSCLC resulted in a high rate of tumor control and low 
rates of radiation induced toxicity for both medically operable and inoperable patients. 
In 2009, the RTOG began two trials using SBRT for early stage NSCLC, RTOG-
0813 for centrally located lesions and RTOG-0915 for peripherally located lesions.10,11 
These studies are frequently referred to in practice today, providing guidelines for treating 
single lesions. Both studies considered lung heterogeneities in the dose calculations. 
Shortly after, the American Society for Therapeutic Radiology and Oncology (ASTRO) 
and the American College of Radiology (ACR), as well as the American Association of 
Physicists in Medicine, published practice guidelines for SBRT.12,13 Results from these 
studies and using the practice guidelines further encouraged clinicians that using SBRT for 
either NSCLC or any localized lung cancer could result in local control rates comparable 
to surgery.14,15 Excellent outcomes were associated with high biological effective doses 
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(BED) of at least 100 Gy, using an α/β ratio of 10 Gy for lung tumors.16 BED aims to 
quantitate the biological effect of radiation therapy, considering the type of tumor and the 
dose delivered.17 By 2013, the radiation community generally agreed that a BED of at least 
100 Gy was necessary for successful lung SBRT.18 Most common lung SBRT prescriptions 
are 50 Gy in 5 fractions (100 Gy BED), 48 Gy in 4 fractions (105.6 Gy BED) and 54 Gy 
in 3 fractions (151.2 Gy BED). SBRT to lung lesions is typically utilized for small volumes 
(3-5 cm), with treatment to larger volumes (>7.0 cm) resulting in higher dose spread and 
chance of radiation induced pneumonitis. Physicians may choose differing prescriptions 
depending on lesions size and proximity to normal structures, such as the ribs or bronchial 
tree. 
In current practice, it is acknowledged that the success of SBRT relies on accuracy 
and confidence throughout the entire process, from patient imaging to treatment planning 
and delivery. Clinics must adapt to continuing improvements in technology, however the 
success of lung SBRT treatments is more likely attributed to the experience of a clinic 
rather than technological advances.19 The external stereotactic body frame with abdominal 
compression maintains a presence in clinics practicing SBRT, however most frames are 
now made without walls and with more robust materials, such as Kevlar. Patients are 
positioned on a vacuum bag with arms up and abdominal compression to minimize tumor 
motion, when possible. If the patient cannot tolerate compression, alternative forms of 
motion evaluation and management are used such as 4DCT, slow CT, breath holds, or 
optical tracking techniques.20-23 Further adapting to improvements in technology, many 
clinics now treat lung SBRT patients with volumetric modulated arc therapy (VMAT).24,25 
VMAT modulates dose rate and multileaf collimator (MLC) position as the gantry rotates. 
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VMAT provides lower dose to non-cancerous structures compared to more traditional 
treatment methods such as static 3D fields, static intensity modulated radiation therapy 
(IMRT) or coplanar dynamic conformal arcs (DCA). Helical Tomotherapy and robotic 
CyberKnife are two alternatives to the traditional C-arm linear accelerator that are used for 
SBRT treatments. However, both Tomotherapy and CyberKnife lung SBRT treatments are 
considerably longer than VMAT on a C-arm linear accelerator.26,27 Even more recently, 
the technique of flattening filter free (FFF) beams (removal of the flattening filter that 
traditionally provides a uniform beam of radiation) has been shown to have considerable 
benefit for lung SBRT by both decreasing treatment time and improving dose coverage at 
the tumor-lung interface.28 
 
1.2 Multiple Lesion Lung SBRT 
There is a large cohort of patients who present with multiple primary or metastatic 
disease in the lung. Lungs are one of the most common sites of metastasis from many 
cancers including colorectal cancer, renal cancer and hepatocellular carcinoma, which can 
all be treated with SBRT.29 In 2006, the first study for bilateral multiple primary lung 
cancers concluded that SBRT is a possible safe and effective treatment option for these 
patients.30 This study was followed by others that reported SBRT as a treatment to 
successfully manage multiple primary lung tumors or oligometastatic disease.31-34 NRG 
Oncology began a study in 2014, NRG-BR001 A Phase 1 Study of Stereotactic Body 
Radiotherapy (SBRT) for the Treatment of Multiple Metastases. This study was intended 
for oligometastases arising from the breast, lung or prostate to determine the tolerability of 
SBRT to multiple lesions. This study was closed in March 2018 with outcomes continuing 
to be reported. Preliminary results from the study indicate that SBRT is safe for 2 lesions 
6 
 
in close proximity and up to 4 lesions irrespective of proximity.35 However, the study 
allowed for virtually any treatment planning parameters including either flattened or FFF 
beams as well as 3D conformal radiation therapy or IMRT/VMAT. It is important to 
acknowledge that, contrary to conventional radiation therapy, SBRT treatments are long. 
The increased time can be attributed to the higher accuracy needed in patient setup, the 
high dose being delivered, the complexity of the plans and the need for pre-treatment 
imaging, typically a cone beam CT scan (CBCT). Hoogeman, Nuyttens, and colleagues 
determined for a subset of immobilized patients intrafraction motion increased linearly 
with time.36 This gives incentive to create treatment plans that can be delivered as quickly 
and accurately as possible. Likewise, most SBRT studies report participants of greater than 
75 years of age. These patients may have a difficult time remaining still and comfortable 
in the treatment position due to associated medical comorbidities. Furthermore, treating 
multiple lesions with SBRT will increase the treatment time.  
To reduce the delivery time for multiple lesion lung SBRT treatments, all lesions 
can be treated at the same time using a single isocenter. Due to the long SBRT times 
reported for both Tomotherapy and CyberKnife, a C-arm linear accelerator using VMAT 
is the most reasonable modality for decreasing treatment times for these patients. Likewise, 
the high dose rate associated with FFF beams can provide highly conformal and faster 
treatments.37 However, there is currently no protocol in place to guide radiation therapy 
clinics in the efficient and accurate treatment of synchronous multiple lung lesions using 
SBRT. Likewise, if the success of SBRT relies on the clinic experience with SBRT, how 
do clinics gain experience without risking patient care? Thus, when a clinic must treat a 
patient with multiple lesions there are questions left unanswered: How should multiple 
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lesions be planned? If to be treated at the same time, what happens if the targets don’t line 
up on the single pre-treatment CBCT? What is the result of slight patient misalignments in 
terms of target dose and dose to critical structures? How can these treatments become more 
efficient? How can we ensure these treatments are safe, effective, and accurate? 
 
1.3 Purpose of Dissertation 
There are no standard guidelines for radiation therapy clinics planning to treat 
synchronous multiple lung lesions with VMAT SBRT. This dissertation aims to create a 
protocol for the fast, safe, effective and accurate treatment delivery of synchronous 
multiple lung lesions using single-isocenter VMAT SBRT. The proposed protocol 
described in this dissertation will simplify the treatment planning and delivery, shorten the 
patient treatment course, improve patient compliance, reduce setup uncertainties and 
support the community with minimal experience treating multiple lung lesions with SBRT. 
 
1.4 Thesis Organization and Clinical Innovations 
Chapter 2 is a dosimetric comparison of two treatment planning techniques 
frequently used in our clinic for two lesion lung SBRT. The first technique consists of two 
plans and two different isocenters, one for each lesion. The second technique plans for both 
lesions to be treated at the same time using a single-isocenter VMAT SBRT plan. The 
isocenter is placed approximately between the two lesions. We hypothesized that the 
single-isocenter plans would be dosimetrically equivalent to multi-isocenter plans, but 
will improve treatment delivery efficiency. It was found that although the two techniques 
provided dosimetrically equivalent plans, treating both lesions with a single isocenter 
reduced the beam-on time by a factor of 1.5. Efficiency of the treatment can improve both 
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patient compliance and clinic workflow. However, lining up both lesions on a single CBCT 
can be difficult and there is no evidence that the single isocenter plans were more accurate 
upon patient setup and delivery. Upon visualization of the setup of previous patient 
treatments, it was observed that small setup errors were possible due to the complications 
of aligning multiple lesions on a pre-treatment CBCT.  
Clinical Innovation #1: Creation of a novel method for simulating patient setup 
errors in six dimensions. 
Our current treatment planning system (TPS) is limited to simulate four dimensions 
(3 translational and 1 rotational), providing disparities with actual treatment delivery. 
Therefore, to account for all six dimensions of patient setup uncertainties, we have 
developed a novel registration approach utilizing transformation matrices created with 
image registrations. Studies that have demonstrated dosimetric effects of patient setup 
errors have relied on external programs created by the user or “third-party” programs that 
are bought by the department. A script was written in MATLAB (Appendix 2) which 
allows for patient images to be transformed which can then be brought into the TPS for 
dose calculation while preserving all treatment planning parameters, including beam 
geometry, MLC positions, and algorithms. This method allows for quick, easy, and 
accurate quantification of the dosimetric effects of patient misalignment. This method has 
already been implemented by other users in clinical research for treatment sites including 
multi-lesion brain stereotactic radiosurgery (SRS) and prostate SBRT. 
Thus, using this novel simulation method (Clinical Innovation #1), Chapter 3 
aims to quantify the loss of target coverage due to patient set up uncertainties in the 
treatment of synchronous multiple lung lesions using single-isocenter VMAT SBRT. We 
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hypothesized that small patient setup uncertainties could lead to clinically 
unacceptable target coverage loss. Using this clinically realistic approach, it was 
determined that target coverage loss is possible due to the setup errors resulting from 
misalignment of multiple lesions on a pre-treatment CBCT. This method was tested on 26 
previously treated patients with two lung lesions each. This deviation from planned target 
coverage was found to be 27.4% on average, but as much as 72% for smaller lesions. 
Consequently, the largest deviations from planned coverage and desired BED were seen 
for the smallest targets (<10 cc), some of which received <100 Gy BED, delivering 
suboptimal SBRT dose. In order to minimize the consequences of these setup errors and to 
provide more accurate and flexible patient treatments, a novel treatment method was 
created.  
Clinical Innovation #2: Creation of Restricted Single-Isocenter Stereotactic Body 
Radiotherapy (RESIST) treatment planning method to minimize setup uncertainties.  
Chapter 4 presents a novel treatment technique, RESIST (Clinical Innovation 
#2). We hypothesized that RESIST could be used to minimize the patient setup errors 
possible in the treatment of multiple lesions using a single isocenter while providing 
efficient treatments. RESIST utilizes a single isocenter placed at the mediastinum. This 
allows a plan to be created for each tumor, while allowing both tumors to be treated 
sequentially during the same session. It uses novel features in Eclipse TPS with dynamic 
conformal arc (DCA)-based dose and user-controlled field aperture shape before VMAT 
optimization. This method can be followed by treatment planners to produce consistent 
plans and more flexible treatment delivery. RESIST was tested using 21 patients with two 
lesions each. This is the first step-by-step protocol for treatment of multiple lung lesions 
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with VMAT SBRT. RESIST increases the accuracy of single-isocenter treatments and the 
subsequent patient setup. This technique is fully supported by our clinical Radiation 
Oncologists and has been clinically implemented.  
Clinical Innovation #3: Automation of the RESIST methodology (a-RESIST), the 
first adaptable automated treatment planning strategy for synchronous multiple lung lesion 
SBRT. This automated RESIST method is clinic specific and can be adapted to fit the 
planning and delivery preferences of the clinic. The a-RESIST method reduces treatment 
planning time, reduces inter-planner variability, and standardizes multi-lesion lung SBRT 
treatments.  
In Chapter 5, RESIST was scripted and automated in Eclipse TPS (Appendix 3) 
to allow for efficient and accurate treatment planning (Clinical Innovation #3). We 
hypothesized that a-RESIST could quickly produce acceptable and consistent 
treatment plans for two lung lesion VMAT SBRT. Automation includes beam geometry, 
algorithms selection, and integration of an in-house trained dose volume histogram 
estimation model to increase the quality and consistency of the plans. The a-RESIST 
method provides guidance for inexperienced planners by standardizing beam geometry and 
plan optimization. To demonstrate feasibility of a-RESIST, 10 patient plans with two lung 
lesions, previously treated with single-isocenter VMAT, were compared. a-RESIST not 
only exhibited similar plan quality to the clinical plans, it significantly reduced the 
treatment planning time to less than 20 minutes and provided a higher dose to the lung 
tumors. This treatment delivery framework allows all patients who are to be treated with 
SBRT to multiple lung lesions to be treated efficiently and effectively. Automated planning 
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is only recently available and this is the first proof of concept for lung SBRT automated 
planning.  
Finally, Chapter 6 discusses the limitations of this study and future research 
directions utilizing the innovative techniques and tools created in this study.   
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CHAPTER 2. EVALUATION OF PLAN QUALITY AND TREATMENT 
EFFICIENCY FOR SINGLE-ISOCENTER/TWO-LESIONS LUNG 
STEREOTACTIC BODY RADIATION THERAPY 
The following chapter has been adapted from a published manuscript: Lana Sanford, 
Janelle Molloy, Sameera Kumar, Marcus Randall, Ronald McGarry, and Damodar 
Pokhrel, "Evaluation of plan quality and treatment efficiency for single‐isocenter/two‐
lesion lung stereotactic body radiation therapy." J Appl Clin Med Phys. 2019;20.1, 118-
127. 
Abstract 
Our goal is to evaluate the plan quality and treatment delivery efficiency of single-
isocenter/two-lesions volumetric-modulated arc therapy (VMAT) lung stereotactic body 
radiation therapy (SBRT). Eight patients with two peripherally located early-stage non-
small-cell-lung cancer (NSCLC) lung lesions underwent single-isocenter highly-conformal 
non-coplanar VMAT SBRT treatment in our institution. A single-isocenter was placed 
between the two lesions. Doses were 54 Gy or 50 Gy in 3 and 5 fractions, respectively. 
Patients were treated every other day. Plans were calculated in Eclipse with AcurosXB 
algorithm and normalized to at least 95% of the planning target volume (PTV) receiving 
100% of the prescribed dose. For comparison, two-isocenter plans (isocenter placed 
centrally in each target) were created. Conformity indices (CIs), heterogeneity index (HI), 
gradient index (GI), gradient distance (GD), and D2cm were calculated. The normal lung 
V5, V10, V20, mean lung dose (MLD) and other organs at risk (OARs) doses were 
evaluated. Total number of monitor units (MUs), beam-on time and patient-specific quality 
assurance (QA) results were recorded. The mean isocenter to tumor distance was 6.7±2.3 
cm. The mean combined PTV was 44.0±23.4 cc. There was no clinically significant 
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difference in CI, HI, GD, GI, D2cm and V20 including most of the OARs between single-
isocenter and two-isocenter lung SBRT plans, evaluated per RTOG guidelines. However, 
for single-isocenter plans as the distance between the lesions increased, the V5, V10 and 
MLD increased, marginally. The total number of MUs and beam-on time was reduced by 
a factor of 1.5 for a single-isocenter plan compared to a two-isocenter plan. The single-
isocenter/two-lesions VMAT lung SBRT QA plans demonstrated an accurate dose delivery 
of 98.1±3.2% for clinical gamma passing rate of 3%/3 mm. The SBRT treatment of two 
peripherally located lung lesions with a centrally placed single-isocenter was 
dosimetrically equivalent to two-isocenter plans. Faster treatment delivery for single-
isocenter treatment can improve patient compliance and reduce the amount of intra-fraction 
motion errors for well-suited patients. 
 
2.1 Introduction 
For medically inoperable stage I/II non-small-cell lung cancer (NSCLC) patients, 
several Phase I/II trials have shown that the use of SBRT treatment for solitary lung lesions 
representing the primary tumor mass is safe, effective and has a high cure rate comparable 
to surgery.1-7 In these studies, medically inoperable patients with early-stage NSCLC who 
underwent stereotactic body radiotherapy (SBRT) had 3-year primary tumor local control 
rates of up to 98% and a low risk of treatment-related toxicity.  
In the setting of either multiple primary lung cancers or limited metastatic lesions 
to the lungs (oligometastastic), SBRT presents a relatively new treatment opportunity. 
Optimal treatment planning must consider microscopic disease extension around the 
visible mass and allow for tumor movement, primarily due to respiration. Multiple 
metachronous or synchronous lung cancers are relatively common and have been managed 
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by SBRT.8 Based on Phase I/II trials of SBRT in the management of oligometastastic lung 
lesions, for patients with one to three tumors, up to five tumors (with curative intent) and 
more than five tumors with palliative treatment have been reported.9,10 Rusthoven and 
colleagues treated thirty-eight patients, 63 total tumors, with lung SBRT of total dose of 
48-60 Gy in 3 fractions. Actuarial local control rates at 1- and 2-year after SBRT was 100% 
and 96%, respectively.10 
SBRT to multiple lung lesions presents with technical challenges and can be treated 
either sequentially with separate treatment plans or synchronously to all lesions. However, 
the location and geometry of synchronous plans can be challenging since minor 
inaccuracies of patient setup can result in geometric misses. Attention must be paid to 
overlapping doses to organs at risk (OARs) and respiratory control is critical since different 
parts of the lung can move independently. Sequential treatment plans for each individual 
tumor, using a multi-isocentric technique, requires relatively longer planning and treatment 
delivery time. Safe and effective delivery of SBRT to the lung requires precise, highly 
conformal treatment planning and delivery techniques.11-15 In the past decades, treatment 
techniques for lung SBRT included Linear accelerator-based 3D-conformal radiation 
therapy, intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy 
(VMAT) (RapidArc,Varian Inc.), CyberKnife and helical Tomotherapy (Accuray Inc.). 
However, as the complexity of the technology has evolved, treatment has required very 
high total monitor units (MU) and relatively long treatment times to deliver a highly 
conformal plan and spare OARs.16-18 
With the recent technological advances, VMAT may provide highly-conformal 
radiation dose delivery with faster delivery times.19-22 VMAT lung SBRT simultaneously 
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optimizes gantry speed, multi-leaf collimator (MLC) position and high dose-rate (FFF, 
flattening filter free mode) to provide highly-conformal dose distributions to the planning 
target volume (PTV) while minimizing dose to adjacent OARs. Reducing treatment time 
would improve patient compliance which helps reduce error due to motion, and promote 
more efficient clinic flow. For multiple brain metastases, recent studies have shown that 
single-isocenter VMAT can provide highly conformal radiosurgical dose distributions, 
excellent plan quality and safe and faster treatment delivery compared to conventional 
multi-isocenter technique.23-25 However, there is little literature in the medical physics 
community on the treatment of multiple lung lesions using single-isocenter VMAT-SBRT 
technique.  
A few studies have examined the use of single-isocenter SBRT for multiple lung 
lesions. A study by Trager et al discusses the use of a technique that utilizes a single-
isocenter with distinct optimizations for extracranial radiosurgery.26 Gulam et al examined 
six patients and found that the criteria set forth by Radiation Therapy Oncology Group 
(RTOG) study 0915 protocol was met with regard to CI, but not for some other critical 
dosimetric parameters.27 A retrospective study of eleven patients by Quan et al showed no 
difference in multiple dosimetric parameters between single-isocenter VMAT plans (four 
single-isocenter VMAT plans were compared) and multi-isocenter intensity-modulated 
SBRT to the lung.28 Still, the ability of a single-isocenter treatment to two or more lung 
lesions to deliver curative treatment plans in adherence with RTOG dosimetric compliance 
criteria has not been fully explored. In this report we present our recently adopted treatment 
method utilizing single-isocenter VMAT plan for SBRT of two lung lesions evaluated per 
RTOG protocols.12-14 For completeness, the original single-isocenter lung SBRT plans and 
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retrospectively generated conventional two-isocenter lung SBRT plans were compared via 
their protocol compliance, plan quality, dose to critical structures, treatment delivery 
efficiency and accuracy.  
 
2.2 Materials and Methods 
2.2.1 Patient setup and Target Delineation 
A total of eight patients were included in this retrospective study, all of whom had 
two peripherally-located Stage I NSCLC lesions. The patients were immobilized using 
Body Pro-LokTM platform (CIVCO system, Orange City, IA) in the supine position with 
their arms above their head with abdominal compression when possible, potentially 
reducing diaphragmatic motion to less than or equal to 1.0 cm. Conventional 3D CT scans 
and for patients unable to tolerated the compression, respiration-correlated 4D CT scans, 
were acquired on a GE Lightspeed 16 slice CT scanner (General Electric Medical Systems, 
Waukesha, WI) with 512 × 512 pixels at 2.5 mm slice thickness. Varian’s Real Time 
Position Management Respiratory Gating System (version 1.7) was used for collection of 
4D CT data.  All 10 phases of 4D CT slices and respiratory motion signal were transferred 
to an Advantage 4D Workstation (General Electric Medical Systems, San Francisco, CA), 
where the maximum intensity projection (MIP) images were generated after a phase 
binning of the 4D CT images. In addition to the MIP images, the motion of both tumors 
was evaluated by an experienced physicist to affirm synchronous tumor motion that was 
less than 1 cm. The regular 3D CT scan and the MIP images were imported into the Eclipse 
treatment planning system (TPS) (version 13.0, Varian Medical Systems, Palo Alto, CA) 
and co-registered for target contouring. Gross tumor volumes (GTV) were delineated on 
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the 3D CT images and, for 4D CT patients, internal tumor volumes (ITV) were delineated 
on the 3D CT images with references to the MIP images. Planning target volumes (PTV) 
were generated by adding non-uniform 5-10 mm margins to the GTV or uniform 5 mm 
margin to the ITV to accommodate the patient setup uncertainties based on tumor size, 
location and synchronous tumor motion. The critical structures, such as bilateral lungs 
excluding the GTV/ITV (normal lung), spinal cord, ribs, heart, great vessels, esophagus, 
and skin were delineated on the 3D CT images.  
 
2.2.2 Treatment Planning 
2.2.2.1 Clinical Single-Isocenter VMAT Plan 
Highly conformal, clinically optimal VMAT treatment plans were generated using 
3-4 non-coplanar partial arcs (5-10o, couch kicks were used for arcs) for the Truebeam 
linear accelerator (Varian, Palo Alto, CA) with millennium MLC and a 6MV-FFF 
(1400MU/min) beam. A single-isocenter was placed approximately between the two 
lesions. As the isocenter location does not need to be exactly in the middle of the lesions, 
an offset allowing for the gantry to rotate in a partial arc can be made. For those arcs, 
collimator angles were chosen in such a way that the opening of the MLC between tumors 
was minimized while the gantry rotates around the patient. Additionally, jaw tracking was 
used to further minimize the out of field leakage dose. The isocenter to tumors distance 
was the maximum 3D-linear distance from the single-isocenter location to the geometric 
center of the individual tumor/isocenter. This distance was calculated in the TPS using the 
x-, y-, and z- primary coordinates of the tumor centers. This distance was estimated to 
evaluate the normal lung doses as a function of isocenter distance from the targets. A dose 
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of 54 Gy or 50 Gy in 3 and 5 fractions, respectively, was prescribed to the PTV D95% and 
planned such that the maximum dose in the GTV was about 120%. All clinical treatment 
plans were calculated using the Eclipse TPS with Acuros-XB (version 13.6.0, Varian 
Medical Systems, Palo Alto, CA) algorithm on the 3D CT images for heterogeneity 
corrections with a 2.0 × 2.0 × 2.0 mm3 dose calculation grid-size. Dose to medium reporting 
mode was selected. All clinical plans were inversely optimized using variation of gantry 
rotation speed, dose rate and MLC positions. The generalized normal tissue objective 
(NTO) parameters were used to control the gradients for single-isocenter clinical plan. As 
recommended by Varian, in our department, we used the following NTO parameters for 
lung SBRT plans: NTO with high priority of 150 with distance to target border of 0.1 cm. 
Start dose of 100.0% and fall dose of 40% was used with 0.5 fall factor. Moreover, the ring 
structures of 5 mm, 10 mm and 20 mm annulus from each lesion with 5 mm gaps were 
generated to enforce the high dose regions (typically enforcing maximum 120% hotspot 
inside each ITV) and minimize the intermediate dose spillage. All the planning objectives 
were per RTOG 0915, RTOG 0813 or RTOG 1021 guidelines. The patients were treated 
every other day per lung SBRT protocol. 
 
2.2.2.2 Two-Isocenter VMAT Plan 
For comparison, the SBRT treatment plans for all patients were retrospectively re-
planned with a conventional two-isocenter approach. Individual isocenters were placed in 
the geometric center of each tumor. For each target, the plans were generated using 3-4 
non-coplanar partial arcs, similar to single-isocenter plan. Collimator rotations and jaw 
tracking were applied. The plan for the first tumor (PTV1) was first computed using same 
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RTOG guidelines as described before. The plan for PTV1 was then used as the base-plan 
for generating the plan for the second tumor (PTV2) in order to allow full scatter 
contributions from both plans. All the planning objectives used were the same as the single-
isocenter plan including the NTO parameters and ring structures. Dosimetric parameters 
for the target coverage and the adjacent OARs, including normal lung, were evaluated. 
 
2.2.3 Plan Evaluation 
Each plan was evaluated for the target coverage and the dose to OARs. For example, using 
the percentage prescribed isodose volume and target size, the RTOG conformity index (CI) 
was calculated as follows:29  
                                               𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝐶𝐶𝐶𝐶 = 𝑅𝑅𝑅𝑅 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 𝑉𝑉𝐼𝐼𝑉𝑉𝑉𝑉𝑉𝑉𝐼𝐼
𝑃𝑃𝑃𝑃𝑉𝑉 𝑣𝑣𝐼𝐼𝑉𝑉𝑉𝑉𝑉𝑉𝐼𝐼
                                                (2.1) 
Ideally, CI = 1.0, implying a perfectly conformal plan. The RTOG recommendation for the 
CI is < 1.2 with 1.2-1.5 being acceptable with minor deviations. In addition, the Paddick 
conformation number (CN) was calculated by:30 
                                               𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐶𝐶𝐶𝐶 = (𝑃𝑃𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃)
2
(𝑃𝑃𝑉𝑉∗𝑃𝑃𝐼𝐼𝑉𝑉)
                                                                 (2.2) 
Where TVPIV is the target volume covered by the prescription isodose volume, TV is the 
target volume and PIV is the prescription isodose volume. CN = 1.0 would be ideal. The 
heterogeneity index (HI) was determined by; 
                                              𝐻𝐻𝐶𝐶 =  𝐷𝐷10%
𝐷𝐷95%
                                                                                              (2.3) 
Where D10% is the dose to the hottest 10% of the PTV and D95% is the dose to the 95% 
of the PTV coverage. The intermediate dose spillage was evaluated by using, gradient 
index (GI), D2cm and gradient distance (GD). The GI was given by; 
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                                                𝑅𝑅𝐶𝐶 = 𝑅𝑅50%
𝑅𝑅100%
                                                                                             (2.4) 
Where R50% is the ratio of 50% prescription isodose volume to the PTV and R100% is 
the ratio of 100% prescription isodose volume to the PTV. Per RTOG, depending on the 
target size, a GI of 3.0-6.0 is desirable. Similarly, D2cm is the maximum dose, in percent of 
dose prescribed, at 2 cm from the PTV in any direction; and the GD, is the average distance 
from 100% prescription dose to 50% of the prescription dose. Although, RTOG only 
recommended normal lung, V20 < 10% (10-15% was acceptable with minor deviations), 
we have evaluated V5, V10 and mean lung dose (MLD) for normal lung for all plans.  
 
2.2.4 Dose to Other OARs 
In addition to the lung dose, all the clinical single-isocenter plans were evaluated 
for dose to spinal cord, heart, esophagus, trachea, ribs and skin per RTOG guidelines. The 
dose volume histogram parameters were compared between the single-isocenter and the 
two-isocenter plans. Data was assessed for normality, then the mean and standard deviation 
values for each of the dose metrics were compared using Student’s t-tests (Microsoft Excel, 
Microsoft Corp., Redmond, WA) or Mann-Whitney test (Minitab, Minitab LLC, Chicago, 
IL) for single-isocenter vs two-isocenter computed dosimetric parameters for the OARs 
dose tolerances using an upper bound of p-value < 0.05. 
 
2.2.5 Delivery Efficiency and Accuracy 
The dose delivery efficiency of each lung SBRT plan was evaluated based on total 
number of MU and actual beam-on time. For the single-isocenter plan, actual beam on time 
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was recorded at the treatment machine while delivering the VMAT-SBRT QA plan. 
Delivery accuracy of the VMAT-SBRT QA plan was evaluated by physically measuring 
the 2D dose distribution of each plan using an Octavius phantom (PTW, Freiburg, 
Germany). All QA plans were delivered at the machine the day before the patient’s 1st 
treatment. The measured cumulative 2D dose plan was compared with the computed dose 
distributions calculated on the Octavius QA phantom plan by the TPS. Upon completion 
of delivered dose, data were analyzed with Octavius MEPHYSTO Navigator (VeriSoft 
Patient Plan Verification, Version 6.3, PTW) using the standard clinical gamma passing 
rate criteria of 3%/3mm maximum dose difference and distance-to-agreement (DTA) with 
10% threshold as well as point dose. Since the two-isocenter plans were not used for patient 
treatment, no VMAT QA was done. The beam on time was estimated by using dose rates 
of 1400MU/min for these plans. 
 
2.3 Results 
2.3.1 Target Coverage and Normal Lung Dose 
All patients were treated with a single-isocenter VMAT plan in our clinic, which 
utilized 2-4 non-coplanar partial arcs. The prescription dose was 50-54 Gy in 3-5 fractions 
for at least 95% of the PTV receiving 100% of the prescribed dose. The single-isocenter to 
tumors distance was calculated in the TPS using the x-, y-, and z- primary coordinates of 
the tumor centers, as described above. The isocenter to tumor distance was approximately 
3.7 to 9.6 cm (mean, 6.7 ± 2.3 cm). The mean combined PTV was 44.0 ± 23.4 cc (range, 
20.5-91.8 cc). The DVHs for both single-isocenter and two-isocenter treatment plans are 
shown in Figure 2.1 for patient #8. In this case, both planning approaches produced 
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dosimetrically equivalent plans. However, the treatment delivery time for the single-
isocenter technique is less than the two-isocenter technique by a factor of 1.5. That was 
just a reported treatment delivery time, the actual patient set up and verification for the 
second isocenter with two-isocenter plan would take extra-time, prolonging the treatment 
delivery. The estimated time for initial patient setup on the machine is about 10 minutes 
and the estimated time to complete one CBCT is 1 minute followed by another about 3 
minutes for tumor matching and applying shifts. Setup and imaging for the second 
isocenter plan is estimated at an additional 8 minutes. 
 
Figure 2.1: The dose volume histogram comparison for the target coverage of Patient 
#8 (for both PTV1 and PTV2). 
The ITVs (red) and a few OAR such as total normal lung (light blue), heart (dark blue), 
ribs (green) and spinal cord (orange) are shown in Figure 2.1 for patient #8. Prescription 
dose was 54 Gy in 3 fractions. The square symbols representing the single-isocenter plan 
and the triangle symbols representing the two-isocenter plan. Both plans were normalized 
to at least 95% of PTV received 100% of the prescribed dose. In this case, the isocenter to 
tumors distance was about 4 cm; the dosimetrically equivalent plans were generated using 
single-isocenter technique, as demonstrated, with similar target coverage and dose to the 
OARs. 
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Figure 2.2 displays a sagittal view of both single-isocenter and two-isocenter 
treatment plans for the same patient (#8). In this case, the normal lung V5 and V10 were 
similar; V20 was slightly higher with single-isocenter plan compared to two-isocenter plan. 
However, both plans met the RTOG compliance criteria for the target coverage (see Table 
2.1), normal lung and the other OARs dose tolerances. 
 
Figure 2.2: Comparison of isodose distributions in sagittal view for patient #8 
generated via single-isocenter and two-isocenter plans. 
In the right panel a single-isocenter location is shown by the intersection of the cross-hair; 
in the left panel two-isocenter plan sum is shown for the both targets (PTV1 and PTV2). 
Target volumes contoured include both ITVs (red, innermost) followed by PTVs (orange 
and green, outermost). Higher isodose lines, such as 54 Gy (100%), 51.3 Gy (95%), 48.6 
Gy (90%), 43.2 Gy (80%), exhibit sharp dose fall off for the both plans, including 27.0 Gy 
(50%) isodose line (blue). In both plans, the hotspot, 120% isodose line (thick-orange) was 
shown in the middle of the ITV. Other OARs such as ribs and lung contours are shown. 
Purple color rings were contoured to calculate D2cm (%) for each target. 
 
 Detail of the plan comparison for target coverage including tumor location and the 
tumors distance from the isocenter are shown in Table 2.1.  
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Table 2.1: Comparison of plan evaluation parameters for single-isocenter vs two-
isocenter treatment plans of all eight lung SBRT patients. 
Patient 
no. 
Plan type 
and 
Tumor 
location 
Combined 
PTV (cc) 
RTOG 
CI 
Paddick 
CN 
HI GI D2cm 
(%) 
GD 
(cm) 
Isocenter 
to tumors 
distance 
(cm) 
1 Lesion 1, 
LUL 
5.0 1.08 0.75 1.16 6.6 47.9 0.90 5.2 
Lesion 2, 
LLL 
16.1 1.01 0.84 1.17 4.1 41.4 0.95 
Two-iso 
(plan 
sum) 
21.1 1.05 0.81 1.18 4.8 47.6 0.97 
Single-
isocenter 
1.05 0.79 1.16 5.0 56.5 1.20 
2 Lesion 1, 
LUL 
30.7 1.01 0.83 1.11 4.2 57.3 1.21 9.5 
Lesion 2, 
RUL 
43.6 0.99 0.84 1.22 3.6 55.2 1.18 
two-iso 
(plan 
sum) 
74.3 1.02 0.80 1.23 4.2 60.2 1.24 
single-
isocenter 
1.02 0.82 1.21 4.6 62.8 1.75 
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Table 2.1 (Continued) 
3 Lesion 1, 
LLL 
16.2 1.05 0.76 1.17 4.8 50.8 1.05 9.6 
Lesion 2, 
RUL 
34.9 1.19 0.68 1.08 5.5 69.2 1.43 
Two-iso 
(plan 
sum) 
51.1 1.26 0.70 1.26 5.4 76.3 1.49 
Single-
isocenter 
1.29 0.67 1.39 6.4 80.5 1.78 
4 Lesion 1, 
LLL 
8.6 1.03 0.80 1.17 4.8 43.2 0.87 4.6 
Lesion 2, 
RUL 
26.6 1.01 0.84 1.20 4.1 51.8 1.11 
Two-iso 
(plan 
sum) 
35.2 1.07 0.76 1.22 4.9 55.9 1.21 
Single-
isocenter 
1.16 0.74 1.18 5.5 53.6 1.45 
5 Lesion 1, 
LUL 
80.9 0.99 0.83 1.15 3.3 56.1 1.34 8.4 
Lesion 2, 
RLL 
10.9 1.02 0.72 1.21 5.0 48.7 0.97 
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Table 2.1 (Continued) 
 Two-iso 
(plan 
sum) 
91.8 1.01 0.81 1.17 3.9 57.6 1.38  
Single-
isocenter 
1.02 0.81 1.16 4.1 56.4 1.68 
6 Lesion 1, 
Ant. LLL 
19.6 1.04 0.77 1.16 4.3 49.3 1.02 4.8 
Lesion 2, 
Post. 
LLL 
7.7 1.20 0.63 1.20 6.7 44.8 1.00 
Two-iso 
(plan 
sum) 
27.3 1.09 0.72 1.19 5.6 50.3 1.11 
Single-
isocenter 
1.03 0.76 1.17 5.3 48.7 1.38 
7 Lesion 1, 
RUL 
13.6 1.04 0.67 1.10 5.3 48.0 1.04 4.9 
Lesion 2, 
LUL 
17.2 1.02 0.78 1.05 4.5 48.6 1.03 
Two-iso 
(plan 
sum) 
30.8 1.05 0.62 1.11 5.6 51.4 1.09 
 
27 
 
Table 2.1 (Continued) 
 Single-
isocenter 
 1.04 0.70 1.16 5.2 48.6 1.43  
8 Lesion 1, 
Post. 
RUL 
13.5 0.99 0.83 1.19 4.3 46.5 0.94 3.7 
Lesion 2, 
Ant. 
RUL 
8.0 1.00 0.80 1.18 5.1 45.4 0.90 
Two-iso 
(plan 
sum) 
21.5 1.04 0.81 1.19 4.8 47.0 1.13 
Single-
isocenter 
1.03 0.81 1.19 5.1 48.9 1.23 
 
All lung SBRT plans were acceptable per RTOG guidelines for the high (CI, HI) 
and intermediate dose spillage (GI and D2cm). In addition, similar results were shown for 
the Paddick CN between the two plans. No clinically significant difference was observed 
in CI, HI, GD, GI and D2cm between single-isocenter and two-isocenter lung SBRT plans 
evaluated per RTOG guidelines by the treating physician. However, the GD values were 
slightly higher with single-isocenter plan of about 3-5 mm, especially for the larger tumor 
distance from the isocenter compared to two-isocenter plan. Clinical significance of higher 
GD values, compared to relatively faster delivery of single-isocenter plan, may need to be 
explored. 
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The absolute differences between single-isocenter and two-isocenter plans for 
normal lung V20, V10, V5 and MLD were listed in the Table 2.2. All patients had V20 
<10-15 % for both treatment plans.  A statistically insignificant difference (p = 0.09) was 
found for the normal lung V20 between two plans. However, V10, V5 and MLD increases 
slightly with single-isocenter plan compared to two-isocenter plan, giving statistically 
significant differences (p = 0.03, 0.01 and 0.03, respectively). Statistically significant p-
values are highlighted in bold (see Table 2.2). Although, V10, V5 and MLD shown 
statistically significant differences, the absolute differences were on the order of less than 
0.8% for V20, 2.8% for V10 and 6.5% for V5) and less than 60 cGy for MLD, on average, 
therefore, we do not expect the differences would be clinically significant.  
Table 2.2: Normal lung doses statistics between single-isocenter and two-isocenter 
plans for all 8 lung SBRT patients. Data is presented as mean ± standard deviation 
(range) and p-values. 
Plan type V20 (%) V10 (%) V5 (%) MLD (Gy) 
two-isocenter 6.7 ± 2.7  
(2.9 to 12.2) 
18.2 ± 6.7 
 (7.2 to 29.9) 
      29.7 ± 10.4  
      (21.1 to 46.5) 
5.4 ± 1.4  
(3.3 to 8.2) 
single-isocenter 7.5 ± 13.4 
 (3.2 to 13.5) 
21.0 ± 8.9  
(7.5 to 36.8) 
36.1 ± 13.8 
 (18.2 to 61.7) 
6.0 ± 1.8  
(3.7 to 9.2) 
p-value p = 0.09 p = 0.03 p = 0.01 p = 0.03 
 
The ratios between single-isocenter and two-isocenter plans for the V20, V10 and 
V5 as a function of isocenter to tumors distance can be seen in Figure 2.3. When the 
isocenter to tumor distance increased, the low dose volume to the normal lung, such as V5 
and V10, was slightly increased. However, 2 of 8 patients had lower values of V20 with 
single-isocenter plan. 
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Figure 2.3: For all 8 lung SBRT patients, the ratios of V5, V10 and V20 of normal 
lung doses calculated by single-isocenter and two-isocenter plans as a function of 
isocenter to tumors distance. 
For the identical planning objectives, the single-isocenter plan gave slightly higher values 
of V5, V10 and V20 by a factor of 1.2, 1.1 and 1.1, on average, respectively, compared to 
two-isocenter plan. This suggests that comparable dosimetric parameters can be obtained 
for the normal lung. However, single-isocenter plan would have considerably faster 
treatment delivery by an almost a factor of 2, eliminating the setup and verification time 
for the 2nd isocenter plan.  
 
 
2.3.2 Dose to Other OARs 
A comparison of other OARs dosimetric parameters for single-isocenter and two-
isocenter plans for all 8 lung SBRT patients is presented in Table 2.3. Critical organs such 
as spinal cord (Dmax, and D0.35cc), heart (Dmax and D15cc), esophagus (Dmax and D5cc), trachea 
(Dmax and D4cc), ribs (Dmax and D1cc) and skin (Dmax and D10cc) were evaluated per SBRT 
protocol guidelines. 
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Table 2.3: Average values of absolute dose differences between single-isocenter and 
two-isocenter plans for parameters of the OARs for all 8 lung SBRT patients. 
Ratio=single-isocenter/two-isocenter. 
OARs Parameters Mean ± SD 
(Gy) 
Range (Gy) Ratio* p-value 
Spinal 
cord 
 
 
 
 
Dmax  0.5 ± 1.1 -0.9 to 2.9 1.05 ± 
0.13 
p = 0.25 
D0.35cc 0.5 ± 1.1  -0.7 to 2.7 1.03 ± 
0.13 
p = 0.62 
Heart 
 
 
 
Dmax 0.9 ± 3.0 -5.4 to 5.0 1.07 ± 
0.14 
p = 0.42 
D15cc 2.0 ± 1.2 0.0 to 3.9 1.15 ± 
0.09 
p = 0.002 
Esophagus 
 
 
 
Dmax 2.1 ± 3.9 -4.5 to 3.5 1.13 ± 
0.23 
p = 0.18 
D5cc 1.9 ± 3.3  -3.3 to 4.6 1.18 ± 
0.31 
p = 0.15 
Trachea 
 
 
 
 
Dmax 0.7 ± 1.8 -5.0 to 5.9 1.13 ± 
0.27 
p = 0.55 
D4cc -0.8 ± 1.8 -4.5 to 1.0 0.96 ± 
0.27 
p = 0.27 
Ribs 
 
Dmax 0.0 ± 3.9 -5.1 to 7.4 0.99 ± 
0.08 
p = 0.98 
D1cc -0.1 ± 2.2 -4.5 to 2.4 0.99 ± 
0.07 
p = 0.91 
Skin Dmax -0.6 ± 1.5 -3.9 to 0.6 0.97 ± 
0.07 
p = 0.28 
D10cc 1.2 ± 1.1 -0.4 to 2.8 1.11 ± 
0.08 
p = 0.02 
 
Absolute dose differences = single-isocenter–two-isocenter. The negative sign 
indicates that the results of the two-isocenter plans were larger than those of single-
isocenter plans. Statistically significant p-values are highlighted in bold.  
The average values of maximum doses to spinal cord, ribs and skin were similar 
(see the average of the ratios in Table 2.3) between the two planning methods. Although, 
the average values of the absolute dose differences and ratios for heart, esophagus and 
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trachea were slightly higher with single-isocenter plan, the average absolute dose 
differences were up to 1-2 Gy. While evaluating those plans per SBRT protocol guidelines, 
those values met the protocol criteria and, therefore, the differences were not deemed 
clinically significant. Almost all p-values were insignificant, except for dose to 15 cc of 
heart (p = 0.002) and dose to 10 cc of ribs (p = 0.02). Both the single-isocenter and two-
isocenter plans were within clinically acceptable limits per RTOG. 
 
2.3.3 Delivery Efficiency and Accuracy 
For single-isocenter plans, the mean values of the total number of MUs and beam 
on time were 6014 (4013 to 10727) and 4.3 minutes (2.9 to 7.7 minutes). Compared to two-
isocenter plans, the total number of MUs and beam on time were reduced by a factor of 
1.5. Furthermore, with two-isocenter plans, the actual patient set up and verification for the 
second isocenter plan would take extra-time, prolonging the treatment delivery. The 
estimated time for initial patient setup on the machine for both techniques is about 10 
minutes and the estimated time to complete one CBCT is 1 minute followed by another 
about 3 minutes for tumor matching and applying shifts. Setup and imaging for the second 
isocenter plan is estimated at an additional 8 minutes. In addition, lower total MUs could 
potentially deliver lower leakage dose. The complete details regarding number of MUs, 
beam-on time, VMAT QA gamma pass rates, and the measured point dose percent 
difference are found in Table 2.4. Since the isocenter location for single-isocenter is 
blocked by the MLC, the maximum point dose was measured in the middle of the targets 
where the maximum fluence was delivered off axis to the two targets and compared to the 
computed VMAT QA plan on Octavius phantom. 
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Table 2.4: The detailed information on total number of MUs and beam-on time for 
the both single-isocenter and two-isocenter plans for all 8 lung SBRT patients. The 
Octavius VMAT-SBRT QA pass rates and point dose measurements for single-
isocenter plans were also shown. 
Patient no. Plan type Total no. of 
MUs 
Beam-on 
time 
(min) 
Gamma pass 
rates 
3%/3mm (%) 
Point 
dose 
% diff. 
(%) 
1 two-isocenter 10069 7.19 --- --- 
single-isocenter 5777 4.13 99.3 0.9 
2 two-isocenter 13198 9.43 --- --- 
single-isocenter 10727 7.66 91.7 1.8 
3 two-isocenter 9095 6.50 --- --- 
single-isocenter 6607 4.72 100.0 1.5 
4 two-isocenter 7185 5.13 --- --- 
single-isocenter 6029 4.31 100.0 2.3 
5 two-isocenter 6219 4.44 --- --- 
single-isocenter 4093 2.92 99.4 0.3 
6 two-isocenter 9047 6.46 --- --- 
single-isocenter 5047 3.61 94.3 0.4 
7 two-isocenter 5608 4.01 --- --- 
single-isocenter 4149 2.96 100.0 0.4 
8 two-isocenter 10500 7.50 --- --- 
single-isocenter 5680 4.06 100.0 0.7 
Mean ± 
SD 
two-isocenter 8865 ± 2330 6.3 ± 1.7 --- --- 
single-isocenter 6014 ± 1963 4.3 ± 1.4 98.1 ± 3.0 1.04 ± 
0.7 
 
The Octavius QA pass rates for the single-isocenter plan was 98.1 ± 3.0%, on 
average, for 3%/3mm clinical gamma pass rate criteria and the point dose measurement 
were within 1%, on average, suggesting accurate delivery of the lung SBRT plan. However, 
for patient #2, the gamma pass rates were around 92% for 3%/3mm criteria. In this case, 
both tumors were relatively large, and the tumor to isocenter distance was relatively large, 
around 9.5 cm. In addition, the tumors were located in bilateral lungs. Therefore, the MLCs 
have to travel a longer distance, providing sub-optimal VMAT QA pass rates. This suggests 
that exceeding 10 cm (isocenter to tumors distance) many not provide a clinically optimal 
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plan with single-isocenter. Since the two-isocenter plans were not used for actual patient’s 
treatment we did not run VMAT QA for those plans.  
 
2.4 Discussion 
In this study, we have presented our initial clinical experiences of a fast treatment 
planning and delivery technique using single-isocenter VMAT plans for SBRT of two lung 
lesions following RTOG protocol guidelines.12-14 Our single-isocenter VMAT plan for 
SBRT of two lung lesions uses 3-4 non-coplanar partial arcs. Transmission between 
individual MLC leaf ends travelling between the two tumors is estimated to be between 
12-28%, which increases the low dose volume of the lung in between the tumors. Our 
technique reduces this dose with the use of jaw tracking and patient specific collimator 
angles. Single-isocenter VMAT-SBRT plans were highly-conformal and achieved 
adequate target coverage (see Table 2.1 for CI, HI, Paddick CN, GI, D2cm and GD) 
compared to conventional two-isocenter plans. For all patients, the single-isocenter plans 
met RTOG guidelines including normal lung V20 and were similar compared to two-
isocenter plans. However, when the isocenter to tumor distance increased, the low dose 
volume to the normal lung, such as V5 and V10, was slightly increased as shown in Figure 
2.3. In addition, the other OARs such as spinal cord, heart, esophagus, trachea, ribs and 
skin dose tolerances were also within protocol. The single-isocenter treatment was well 
tolerated with all patients. The beam on time was 4.3 minutes and VMAT-SBRT QA 
gamma passing rates were 98.1% (3%/3mm clinical gamma passing criteria), on average, 
demonstrating an excellent potential for a fast, reliable and accurate delivery of single-
isocenter VMAT lung SBRT treatment for two lung lesions.  
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The single-isocenter plan for treating multiple lung tumors has been reported by a 
few investigators.31,32 For instance, using both coplanar and non-coplanar 9 field IMRT (in 
Pinnacle TPS), Zhang et al compared those IMRT plans with helical Tomotherapy for 
single-isocenter/multi-target lung SBRT treatment.31 The prescription was 60 Gy in 3 
fractions. In their study, it was concluded that compared to IMRT, helical Tomotherapy 
gave better target coverage at the cost of overall 73.0 ± 20.6 minutes treatment time. 
However, IMRT treatment time was not reported. It was also highlighted that compared to 
IMRT plans, Tomotherapy plan also gave a relatively higher normal lung V5. Another 
study by Li et al reported that they treated two patients with single-isocenter lung SBRT 
plan for more than 5 lung metastases.30 Their prescription doses were 48 Gy/8 fractions for 
Patient A (5 tumors) and 42 Gy/7 fractions for patient B (7 tumors). Plans were generated 
in Monaco TPS (CMS Software Inc., St Louis, MO) using a few partial-arcs and delivered 
with Elekta Axesse linear accelerator with 6MV beam (660MU/min). The beam on time 
for each treatment was about 10 minutes. Both patients were followed up, and the treatment 
was well tolerated by the patients with a minimal toxicity. In contrast, utilizing 6MV-FFF 
beam (in Eclipse) for a Truebeam Linac, our single-isocenter VMAT planning technique 
delivered a fast (average beam on time 4.3 min) and potentially effective treatment 
(curative high biological effective dose of >100-150 Gy for each lesion). 
One potential concern for single-isocenter VMAT-SBRT plan for two lung lesions 
was low dose spill in the normal lung, such as V20, V10 and V5. Per RTOG 
recommendation, all our single-isocenter/two-lesions VMAT lung SBRT plans had V20 
<10-15%. Moreover, normal lung V5 was maintained less than 40%, on average.33-35 
Although, in our experience when the isocenter to tumor distance increased, the normal 
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lung V10 and V5 slightly increased, as expected, when compared to two-isocenter plan. 
Our treatment planning strategy favored minimizing normal lung dose during single-
isocenter VMAT planning by optimizing patient specific collimator angles in conjunction 
with jaw tracking such that the leakage dose due to the leaf travel in between two tumors 
could be minimized. This could potentially help reduce severe lung toxicity with careful 
attention to V5 and V10 during plan optimization.  
Another potential concern for single-isocenter VMAT plan was the patient set up 
errors, for example tumor motion and rotational errors. This may result in geographic miss 
and compromise the local tumor control rates. The single-isocenter/two-lesion VMAT plan 
isocenter was generally chosen at the midpoint of the two lesions, therefore, the isocenter 
distance between two lesions was evenly distributed. However, it would be difficult to find 
a perfect midpoint for non-coplanar lesions. The variability of respiratory patterns between 
the CT simulation and the time of treatment was studied by many researchers.36-39 It has 
been reported in the literature that there were only small changes (within ±3 mm) due to 
intrafractional and interfractional motion while using conventional multi-isocenter lung 
SBRT treatment. Their mean patient set up time from tumor localization to the end of 
treatment CBCT scan was about 40 min.38, 39 It was recommended that a 5 mm PTV margin 
was sufficient to address those motion errors. Furthermore, the spatial uncertainties for this 
kind of beam arrangement was discussed by Gary A. Ezzell for single-isocenter/multitarget 
cranial radiosurgery.40 It was demonstrated that with a Truebeam CBCT the maximum 
spatial uncertainties were less than 1.5 mm at 10 cm distance from the isocenter tested 
using 12 target BBs in a phantom. Before delivering each SBRT treatment, a daily QA 
check on kilovoltage to megavoltage imaging isocenter coincidence was performed, 
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including IsoCalc test for precise and accurate target localization. Our IsoCalc localization 
accuracy for Truebeam was < 0.5 mm at isocenter. All the quality assurance procedures 
complied for SBRT treatment delivery. Our image guidance CBCT matching parameters 
(at Truebeam) were consistent with previous findings. Our average beam on time of about 
4.3 minutes per treatment could potentially decrease the possibility of breathing changes 
from coughing or pain and making geographic miss unlikely, potentially improving patient 
stability.  
In addition, due to rotational errors, for small targets and those away from the 
single-isocenter could potentially alter the dose distributions. For those highly conformal 
VMAT plans, the small deviation of motion error could potentially irradiate normal tissues, 
and it may increase the chance of radiation-induced toxicity or miss the target. Our 
attending physician has addressed this issue by individually reviewing these target volumes 
and the associated tumor motion pattern and by assigning appropriate ITV to PTV margins 
(usually 5 mm in the medio-lateral and anterior-posterior directions and 8 to 10 mm in 
superior-inferior direction) to accommodate potential tumor deformation. Moreover, great 
care has been taken by our treating physician and the physicist to address some of the 
above-mentioned issues, for example, being available for the patient set up (in the 3D, 4D 
CT simulation and each treatment), image guidance and CBCT matching and physically 
authorizing each treatment fraction for all patients.  
In summary, each plan was rigorously evaluated using the dosimetric parameters 
listed in Tables 1, 2, and 3. All parameters were deemed acceptable for both single-
isocenter and two-isocenter plans per SBRT protocol, suggesting that single-isocenter 
plans could be dosimetrically equivalent to two-isocenter plan with a faster and equally 
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effective treatment delivery which can be offered to well suited patients. In the future, these 
patients will be followed up clinically and evaluated for local control rates and treatment 
related toxicity such as the effect of normal lung dose as a function of isocenter to tumors 
distance. Moreover, single-isocenter VMAT plan for SBRT of lung for more than two 
lesions will be investigated. 
 
2.5 Conclusion 
This report presents our initial clinical experience with a single-isocenter for two-
lesion SBRT procedure for lung tumors compared with conventional two-isocenter plans. 
Treatment of peripherally located two lung lesions with a centrally assigned single-
isocenter was dosimetrically equivalent to two-isocenter plans. For single-isocenter plans, 
it was observed that as the distance between the lesions increased the normal lung V5, V10 
and MLD somewhat increased. The single-isocenter technique was fast, accurate and well 
tolerated by all the patients, improving patient comfort and potentially reducing the amount 
of intra-fraction motion errors for well-suited patients. Clinical follow up of these patients 
is warranted to determine the tumor local control rates and treatment related toxicity. 
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CHAPTER 3. RISK OF TARGET COVERAGE LOSS FOR STEREOTACTIC BODY 
RADIOTHERAPY TREATMENT OF SYNCHRONOUS MULTIPLE LUNG 
LESIONS VIA SINGLE-ISOCENTER VOLUMETRIC MODULATED ARC 
THERAPY 
The following chapter has been adapted from a manuscript revised and under 
review for publication: Lana Sanford Critchfield, Mark Bernard, Marcus Randall, Ronald 
McGarry, Damodar Pokhrel, “Risk of Target Coverage Loss for Stereotactic Body 
Radiotherapy Treatment of Synchronous Lung Lesions via Single-Isocenter Volumetric 
Modulated Arc Therapy”, J Appl Clin Med Phys, August 22, 2020. 
Abstract 
Treating multiple lung lesions synchronously via single-isocenter volumetric 
modulated arc (VMAT) stereotactic body radiation therapy (SBRT) improves treatment 
efficiency and patient compliance. However, aligning multiple lung tumors accurately on 
one single pre-treatment cone beam CT (CBCT) can be problematic. Tumors not correctly 
aligned could lead to target coverage loss. To quantify this potential target coverage loss 
due to small, clinically realistic setup errors, a novel simulation method was developed. 
This tool was used on twenty-six previously treated patients with two metastatic lung 
lesions. Patients were treated with 4D-CT based, highly conformal non-coplanar VMAT 
plans (clinical VMAT) with 6MV-flattening filter free (FFF) beam using AcurosXB dose 
calculation algorithm with heterogeneity corrections. A single isocenter was placed 
approximately between the lesions to improve patient convenience and clinic workflow. 
Average isocenter to tumor distance was 5.9 cm. Prescription dose was 54Gy/50Gy in 3/5 
fractions. For comparison, a plan summation (simulated VMAT) was executed utilizing 
randomly simulated, clinically relevant setup errors, obtained from pre-treatment set up, 
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per treatment fraction, in Eclipse treatment planning system for each of the six-degrees of 
freedom within ± 5.0 mm and ± 2o. Simulations yielded average deviations of 27.4% (up 
to 72% loss) (p < 0.001) from planned target coverage when treating multiple lung lesions 
synchronously using a single-isocenter plan. The largest deviations from planned coverage 
and desired biological effective dose (BED10) were seen for the smallest targets (<10 cc), 
some of which received <100 Gy BED10. Patient misalignment resulted in substantial 
decrease in conformity and increase in the gradient index, violating major characteristics 
of SBRT. Statistically insignificant differences were seen for dose to normal tissues. The 
authors recommend alternative treatment planning strategies to minimize the probability 
of a geometric miss when treating small lung lesions synchronously with single-isocenter 
VMAT SBRT plans. 
 
3.1 Introduction 
Stereotactic body radiation therapy (SBRT) has become a standard of care 
for selected early stage non-small-cell lung cancer (NSCLC) patients.1-4 Furthermore, 
SBRT of solitary primary or metastatic lung lesions is a fast, safe and effective treatment 
option with a high control rate comparable to surgery.4 For elderly medically inoperable 
patients, SBRT treatment has been shown to be effective.5 However, elderly patients or 
those with poor pulmonary function and multiple oligometastastic (< 5 lesions) lung lesions 
may not retain their treatment position for long SBRT treatment times. Traditional SBRT 
treatment to lung lesions requires an individual plan for each lesion with a separate 
isocenter placed in each, prolonging patient set up and treatment time. Treating multiple 
lung lesions synchronously with a single-isocenter plan, either using intensity modulated 
radiation therapy (IMRT) or volumetric arc therapy (VMAT), has been studied.6-9 Single-
40 
 
isocenter/multi-lesion VMAT lung SBRT treatments have been shown to be fast and 
efficient improving patient comfort14-18 Additionally, treatment efficiency and dose build-
up at the tumor-interface is improved with use of a flattening filter free (FFF) beam.10-13 
This faster treatment option could potentially reduce intrafraction motion errors and 
improve patient compliance.14 
Despite the growing interest in single-isocenter/multi-lesion VMAT lung SBRT 
treatments, there is a decrement in accuracy when treating multiple lesions synchronously 
compared to treating the lesions individually. When each lesion is treated separately, the 
treatment plan has an isocenter in the center of the lesion, and daily conebeam CT 
alignment corrections can be made focusing on that lesion. Single-isocenter/multi-lesion 
VMAT plans are not robust against set up errors because one or all lesions could be offset 
from the single-isocenter location, potentially resulting in less accuracy. Moreover, in 
many treatment planning systems (TPS) including Eclipse TPS (Varian Medical Systems, 
Palo Alto, CA), there is no way to simulate residual set up errors in all six-degrees of 
freedom (6DoF) without using “third party” software. Herein is described a simple and 
clinically useful method for demonstrating the dosimetric effects of setup errors in Eclipse 
TPS. To simulate and quantify possible treatment inaccuracy, this tool uses simulation CT 
images for generating a lung SBRT treatment plan, identical beam data and original clinical 
treatment plan including dose calculation algorithm, without introducing additional sources 
of errors, thus only simulating the dosimetric effects of patient set up uncertainties. 
Utilizing this method, it is demonstrated that when treating multiple lung lesions with a 
single-isocenter VMAT-SBRT plan, small but clinically representative setup errors may 
result in unacceptable loss of target coverage and unintended dose to normal tissues. 
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This comparison was undertaken to quantify the dosimetric impact of residual set 
up errors on target coverage and collateral dose to adjacent organs-at-risk (OAR) in the 
context of single-isocenter VMAT SBRT treatment of multiple lung lesions. Lung SBRT 
literature suggests that a biological effective dose (BED10) of ≥ 100 Gy (α/β = 10 Gy) to 
each lesion is required for optimal tumor local control (LC) and overall survival.19, 20 Olsen 
and colleagues reported clinical outcomes of 130 lung SBRT patients treated with 3 
different dosing schemes. They demonstrated that lung SBRT treatments to 45 Gy in 5 
fractions (85.5 Gy BED10) provided inferior tumor LC rate (50% LC at 2 years) compared 
to 50 Gy in 5 fractions (100% LC at 2 years) and 54 Gy in 3 fractions (91% LC at 2 years), 
suggesting that at least 100 Gy BED10 is necessary. Thus, in addition to evaluating the 
loss of target coverage, this simulation study compared planned versus simulated BED10 
to each lesion.  
 
3.2 Materials and Methods 
After obtaining Institutional Review Board approval, 26 patients with two 
synchronous lung tumors who underwent single-isocenter VMAT lung SBRT treatment of 
54 Gy in 3 fractions or 50 Gy in 5 fractions were included in this study.  
 
3.2.1 Patient Setup and Contouring 
Patients were immobilized using the Body Pro-LokTM SBRT system (CIVCO, 
Orange City, IA) in the supine position with arms up. A free-breathing CT was obtained 
on a GE Lightspeed 16 slice CT scanner (General Electric Medical Systems, Waukesha, 
WI) with 512 × 512 pixel image size and 2.5 mm slice thickness in the axial helical mode. 
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Respiratory assessment and motion management included abdominal compression (n=21) 
or 4D-CT scan (n=5) utilizing Varian RPM system (version 1.7). The 3D-CT scan was 
brought into Eclipse Treatment Planning System (Version 15.6, Varian Medical Systems, 
Palo Alto, CA). Both gross tumor volumes (GTV’s) were contoured on the 3D-CT. If a 
4D-CT was obtained, an internal target volume (ITV=GTV) was contoured based on the 
registered 4D-CT reconstructed maximum intensity projection (MIP). The planning target 
volumes (PTV’s) were created either by expanding a uniform margin of 5 mm from the 
ITV or in the case of no 4D-CT, 5 mm expansion of the GTV in the lateral direction and 
10 mm expansion in the superior-to-inferior direction. The names of the PTVs (PTV 1 or 
PTV 2) were arbitrarily chosen by the treating physician. All planning was done on the 
free-breathing CT and Houndsfield units (HU) within the PTV were maintained per the CT 
dataset. Average PTV size was 20.4 ± 16.2 cc (4.7–80.9 cc). Distance to isocenter was 
determined by finding the coordinates of the PTV geometric center and calculating 
Euclidian distance in 3D geometry with the isocenter coordinates. Critical structures were 
contoured including lungs (right, left and combined), cord, heart, bronchus, trachea, 
esophagus, skin and ribs (right, left and combined). Tumor characteristics for the cohort 
are summarized in Table 3.1. 
Table 3.1: Main tumor characteristics of the 26 lung SBRT patients included in this 
study. Each patient had 2 tumors. STD = standard deviation. 
Parameters Mean ± STD (range or n = no. of 
patients) 
Tumor 1, PTV1 (cc) 
Tumor 2, PTV2 (cc) 
 22.0 ± 19.7 (5.0 – 80.9) 
17.5 ± 11.6 (4.7 – 43.6) 
Prescribed dose to each lesion 54 Gy in 3 fractions (n = 7) 
50 Gy in 5 fractions (n = 19) 
Isocenter to tumors distance (cm) 5.9 ± 2.5 (range: 2.1–11.5) 
Tumor location (left/right/bilateral) (n = 7 / 7 / 12) 
Uninvolved lung (cc) = lungs minus both PTV 3696.4 ± 1059.7 (1921.6 – 6785.6) 
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3.2.2 Clinical Single-Isocenter VMAT Plans 
For all 26 patients, single-isocenter VMAT lung SBRT plans were generated in 
Eclipse TPS for treatment on a Truebeam Linac (Varian Medical Systems, Palo Alto, CA) 
consisting of standard millennium 120 MLC and 6 MV‐FFF (1400 MU/min) beam. A 
single isocenter was placed approximately midway between the two tumors. Doses were 
54 Gy or 50 Gy in 3 or 5 fractions, respectively. Both PTVs (PTV 1 and PTV 2) were 
planned with dose prescribed to the 80% isodose line and optimized such that 95% of each 
PTV received 100% of the prescription dose. The maximum dose to the PTV fell inside 
the GTV. Full arcs (co-planar) were utilized for bilateral lung tumors and partial non-
coplanar arcs utilized for uni-lateral lung tumors, with ± 5-10° couch rotations. Optimal 
collimator angles and jaw-tracking was chosen to reduce MLC leakage between each arc. 
Dose was calculated using Boltzmann transport based AcurosXB algorithm for 
heterogeneity corrections with dose to medium reporting mode.21-23 Planning objectives 
followed RTOG guidelines.24, 25 Each of the clinical VMAT plans was delivered to the 
patient in the clinic.  
 
3.2.3 Simulated Single-Isocenter VMAT Plans 
To evaluate patient setup uncertainties, clinically observable setup errors in all 
6DoF were simulated in Eclipse TPS. Evaluation of pre-treatment cone beam CT scans for 
single-isocenter VMAT treatments allowed for determination of clinically representative 
random setup errors to be within ± 5 mm in the x-, y-, and z-direction and within ± 2° for 
pitch, yaw and roll. The translational errors were defined for isocenter displacements. The 
rotational errors were defined for patient rotations relative to the isocenter around the right-
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left (pitch), anterior-posterior (yaw) and superior-inferior (roll) directions. Since 
demonstrating the loss of target coverage due to setup errors in current Eclipse TPS in all 
6DoF was not readily accessible, an in-house MATLAB (Math Works, MA USA) script 
(Appendix 2) and simulation method was developed in order to achieve the desired 
transformations and re-compute the simulated VMAT plan. The in-house script utilizes a 
RE DICOM file that is created with an image registration module in Eclipse. This RE 
DICOM file consists of the patient CT registered to itself, thus the transformation matrix 
between the two images will be null. The MATLAB script utilizes a random number 
generator to re-write the transformation matrix of one of the identical patient CT datasets 
to apply translations and rotations within the determined range of possible shifts. The 
random number generator utilized creates uniformly distributed random number, thus the 
transformation likely simulates the worst-case scenario for patient setup errors. The image 
registration workspace in Eclipse TPS allows for visualization of these rigid 
transformations in all 6DoF. This is repeated for the number of fractions, with the original 
plan copied to the transformed image. The result of the simulation process is a plan 
summation of all 3 or 5 randomly transformed treatment fractions that mimics day-to-day 
clinical scenarios, allowing for evaluation of a clinically representative single-
isocenter/multi-tumor VMAT lung SBRT treatment. Figure 3.1 below demonstrates the 
steps taken to achieve a complete simulated VMAT plan. Figure 3.2 demonstrates 
randomly transformed CT images, used for one treatment (out of 5 fractions) of a 
representative plan. 
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Figure 3.1: The workflow describes the steps required to complete simulation of 
isocenter misalignment in Eclipse TPS in all six dimensions. 
It utilizes image registration and the external beam treatment planning modules in 
Eclipse. The result is a plan summation of all treatment fractions that have been 
individually and randomly transformed, representing a clinically realistic treatment 
scenario. 
 
Figure 3.2: A demonstration of randomly rotated (within, ± 2°) and translated 
(within, ± 5 mm) CT data set (see bottom right inset) around the plan isocenter 
location (cross-hair) for a representative patient (one fraction). 
The PTVs are shown in orange and pink and the GTVs are in red in both lungs. Normal 
tissue structures are shown: lungs (light blue and green), skin (purple), cord (yellow), and 
ribs (blue). This patient was treated for 50 Gy in 5 fractions to both tumors, thus the random 
transformation process was repeated for a total of 5 treatments (see top left inset). 
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3.2.4 Plan Comparison 
All plans were compared per RTOG guidelines for target coverage along with 
maximum and volumetric dose to the adjacent OAR. Normal tissues that were evaluated 
included maximum dose to 0.03 cc of ribs, spinal cord, heart, bronchial tree, esophagus 
and skin. Lung doses were evaluated using the mean lung dose (MLD), percentage of lung 
receiving 10 Gy (V10Gy) and 20 Gy (V20Gy) or more. Distance to isocenter was 
determined by utilizing the coordinates of the geometric center of each PTV as described 
above. In addition to the OAR doses, both plans were rigorously evaluated using the 
following metrics: 
• Plan maximal dose: Maximum dose in the target 
• Conformality Index (CI): Ratio of prescription isodose volume to the PTV volume. 
Values between 1.0–1.2 are desirable, but values between 1.2–1.5 would be 
acceptable per protocol with minor deviations. Therefore, for prescription isodose 
volume (VRI), 
𝐶𝐶𝐶𝐶𝑅𝑅𝑃𝑃𝑅𝑅𝑅𝑅 =
𝑉𝑉𝑅𝑅𝑃𝑃
𝑃𝑃𝑃𝑃𝑉𝑉
                                                             (3.1) 
• Paddick Conformation Number (PCN): Determines the overlap of the prescription 
isodose volume and the PTV volume. Ideally, PCN = 1.0. For target volume 
covered by the prescription dose (PIV), and total volume covered by the 
prescription dose (VRI), 
𝑃𝑃𝐶𝐶𝐶𝐶𝑃𝑃𝑃𝑃𝐼𝐼𝐼𝐼𝑃𝑃𝑃𝑃𝑃𝑃 =
𝑃𝑃𝑃𝑃𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃
2
(𝑃𝑃𝑃𝑃𝑉𝑉×𝑉𝑉𝑅𝑅𝑃𝑃)
                                           (3.2) 
• Heterogeneity Index (HI): Evaluates the dose heterogeneity inside the PTV, 
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                                               𝐻𝐻𝐶𝐶 = 𝐷𝐷𝑀𝑀𝑀𝑀𝑀𝑀
𝑅𝑅𝑅𝑅
                                                                   (3.3)                                                   
• Gradient Index (GI): Used to evaluate the intermediate dose fall off, 
                                        𝑅𝑅𝐶𝐶 = 50%𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑉𝑉𝐼𝐼𝑉𝑉𝑉𝑉𝑉𝑉𝐼𝐼
𝑃𝑃𝐼𝐼𝑉𝑉
                                             (3.4) 
• Maximum dose at 2 cm away from the PTV in any direction (D2cm): Acceptable 
values depend on PTV size.  
• Biological Effective Dose (BED10): For each PTV, BED10 was calculated using 
the prescribed dose to PTV D95% (Gy). For each GTV, BED10 was determined 
using the minimum dose (d) per fraction to the GTV. An α/β ratio of 10 Gy was 
used for the pulmonary tumor and for n = number of treatments, the BED10 was 
calculated using the following formula: 
           𝐵𝐵𝐵𝐵𝐵𝐵10 = 𝑛𝑛 × 𝑃𝑃 �1 + 𝐼𝐼
𝛼𝛼 𝛽𝛽⁄
�                                      (3.5) 
 
3.2.5 Statistical Analysis 
Data was assessed for normality, then either a paired two‐tail Student’s t‐test 
(Microsoft Excel, Microsoft Corp., Redmond, WA) or a Mann-Whitney test (Minitab, 
Minitab LLC, Chicago, IL) was used to compare the data for the clinical VMAT versus 
simulated VMAT plans for all parameters of target coverage and dose tolerances to OAR. 
A value of p < 0.05 was considered statistically significant. 
 
3.3 Results 
After simulation of setup errors, all PTVs had loss of dose coverage as well as some 
ITVs and GTVs. Simulated VMAT plans demonstrated an average PTV coverage loss of 
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27.4 ± 14.6%, with a maximum loss of 71.7% compared to the original clinical plans. Table 
3.2 shows the analysis of target coverage for all 52 lesions. After the random 
transformations were applied, statistically significant decreases in PTV dose coverage, CI, 
PCN, and HI were observed. The drastic decrease in average CI and PCN for the simulated 
plans suggests that the prescription isodose volume was not covering the PTV as originally 
intended. It is important to note that for one patient the proximity of the lesions resulted in 
dose bridging between the lesions and thus a large CI of 2.69 was evaluated for one PTV, 
which was reduced to 1.33 for the simulated plan. The GI increased from 5.24 ± 1.21 (3.66–
8.31) for the original plans to 8.38 ± 3.78 (3.89–23.76) for the simulated plans. This 
suggests that due to small rotational and translational set up errors, there was significantly 
higher intermediate dose spillage, and the sharp dose fall off indicative of lung SBRT 
treatments no longer existed. For the smaller (<10 cc) target sizes, clinically unacceptable 
GI up to 23.76 was observed (see Table 3.2).  
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Table 3.2: Analysis of the dosimetric and delivery parameters for 26 lung SBRT 
patients treated with a single-isocenter/multiple-target VMAT plan. Mean ± STD 
(range) and p-values were reported for clinical VMAT and simulated plans. n. s. = 
not significant. Significant values are highlighted in bold. STD = standard deviation. 
PCN = Paddick Conformation Number. 
Target Parameter Clinical VMAT Simulated VMAT p-value 
PTV  
(n = 
52) 
Max target 
dose (%) 
122.5 ± 3.8 (115.4–
131.1) 
121.6 ± 3.1 (115.3–
128.6) 
n. s. 
% Volume 
covered by Rx 
dose (%) 
96.1 ± 1.2 (95.0–
98.8) 
68.7 ± 14.7 (25.6–95.2) p < 0.001 
CI 1.08 ± 0.25 (0.95 – 
2.69) 
0.75 ± 0.19 (0.26 – 
1.33) 
p < 0.001 
PCN 0.89 ± 0.03 (0.81 – 
0.98) 
0.64 ± 0.13 (0.26 – 
0.85) 
p < 0.001 
HI 1.21 ± 0.04 (1.13 – 
1.31) 
1.20 ± .04 (1.12 – 1.29) p = 0.03 
GI 5.37 ± 0.94 (3.66 – 
7.2) 
8.36 ± 3.7 (3.89 – 
23.76) 
p < 0.001 
D2cm (%) 51.7 ± 5.6 (38.8 – 
67.0) 
51.7 ± 5.1 (42.4 – 62.3) n. s. 
GTV  
(n = 
52) 
% Volume 
covered by Rx 
dose (%) 
100 ± 0  99.4 ± 2.2 (87.7 – 
100.0) 
p = 0.02 
ITV 
(n=10) 
% Volume 
covered by Rx 
dose (%) 
100 ± 0 99.3 ± 1.3 (95.7-100) n.s. 
 
For all 52 lesions, the average GTV coverage loss following the random 
transformations was 0.6%. However, for PTV volumes less than 10 cc, the GTV coverage 
loss was the greatest at an average of 1.6%, with a maximum loss of up to 12.3% in some 
cases. For the subset of patients with an ITV (n=5), statistically insignificant coverage loss 
following the random transformation was 0.7%. 
The greatest target coverage loss was seen with the smallest PTV sizes. For PTV 
volumes less than 10 cc (n = 14), the relative dose error for the simulated VMAT plans was 
-39.8 ± 18.3% with respect to the clinical VMAT plans. For PTV volumes greater than 10 
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cc (n = 38), the average relative dose error was -19.8 ± 6.1%. Figure 3.3 demonstrates the 
trend in relative dose error with respect to PTV sizes while the relative dose error binned 
by PTV volume is shown in Figure 3.4. However, no obvious correlation between the PTV 
coverage loss and distance to isocenter was observed, as shown in Figure 3.5. It indicates 
that random translational shifts dominated the loss of target coverage in these clinically 
descriptive simulations. However, the largest coverage loss with greater than 50% was 
observed for those lesions with the smallest target size of about 5.0 cc. Figure 3.6 
demonstrates BED calculated utilizing the minimum dose received by the GTV, whereas 
the BED10 for the PTV was calculated using the dose covering 95% of the PTV volume 
as described above. 
 
Figure 3.3: Loss of target coverage for all 52 lesions plotted as a function of PTV size.  
The curve fit (R2 = 0.43) indicates a probable correlation between the target size and 
coverage loss, suggesting that setup errors will result in a larger coverage loss for small 
PTV sizes. 
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Figure 3.4: Loss of target coverage for all 52 lesions as a function of binned PTV sizes. 
The largest coverage loss was seen for lesions less than 10 cc. Target sizes ≤ 10 cc exhibited 
average coverage losses of 40%, up to 70% in some cases. The corresponding GTV loss 
for this subset was an average of 1.6%, up to 12.3% in some cases. 
 
Figure 3.5: Scatter plot of relative dose error for all 52 lesions as a function of distance 
to isocenter. 
For randomly assigned rotational [± 2o] and translations [± 5 mm] errors in each direction, 
no clear relationship between the loss of target coverage and distance to isocenter was 
observed suggesting that random translational shifts dominated the loss of target coverage. 
However, the largest coverage loss (>50%) was seen for those lesions with the smallest 
PTV of about 5 cc. 
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Figure 3.6: Comparison of calculated BED10 for both PTV and GTV for all 52 targets 
is shown for both plans. 
For patients treated with 54 Gy in 3 fractions, >100 Gy BED10 was always preserved for 
each PTV and GTV even with residual set up errors. However, for patients treated with 50 
Gy in 5 fractions (see left panel), the average BED10 for PTV and GTV were 81.5 Gy and 
104.4 Gy, respectively, with simulated VMAT plans compared to 100.0 Gy and 113.0 Gy 
BED10 with original VMAT plans, suggesting that there is a risk of underdosing targets 
due to set up errors. However, on average, the greatest is PTV coverage with less change 
in the GTV BED10. 
 
Table 3.3 shows the comparisons of maximal doses to normal tissue structures. In 
contrast, the maximum dose to the skin, ribs, and esophagus were all lower for the 
simulated VMAT plans and were statistically significant, however likely not clinically 
significant. The largest decrease in maximal ribs dose for one patient was 10.9 Gy in which 
case both lesions (PTV1, 5.0 cc and PTV2, 16.1 cc) were proximal to the chest wall. 
Despite the loss of target coverage for the PTVs demonstrated in Table 3.2, the normal 
lung V20Gy, V10Gy, and MLD did not change significantly suggesting that the doses 
intended for the PTVs were not subsequently deposited in the uninvolved lungs.  
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Table 3.3: Analysis of the maximal dose to OAR for 26 lung SBRT patients. Mean ± 
STD (range) and p-values were reported for clinical VMAT and simulated VMAT 
plans. n. s. = not significant. Significant values are highlighted in bold. STD = 
standard deviation.   
Maximal 
dose to 
OAR & 
uninvolv
ed lung 
  
Parameter Clinical VMAT Simulated VMAT p-value 
Skin (Gy) 17.7 ± 3.6 (11.0 – 26.6) 16.8 ± 3.5 (10.4 – 
25.8) 
p < 
0.001 
Ribs (Gy) 45.2 ± 11.2 (22.5 – 59.0) 42.8 ± 9.2 (24.7 – 
59.1) 
p = 
0.003 
Spinal cord 
(Gy) 
10.5 ± 3.3 (4.7 – 15.5) 10.6 ± 3.5 (4.5 – 
16.1) 
n. s. 
Heart/Pericardi
um (Gy) 
21.1 ± 11.5 (0.9 – 52.0) 20.5 ± 11.8 (0.9 – 
54.2) 
n. s. 
Bronchus (Gy) 18.2 ± 11.9 (0.8 – 50.4) 17.9 ± 12.4 (0.7 – 
51.1) 
n. s. 
Esophagus (Gy) 16.2 ± 8.2 (5.7 – 43.5) 15.8 ± 8.1 (5.6 – 
41.9) 
p = 
0.005 
V20Gy (%) 6.8 ± 4.1 (2.1 – 17.0) 6.9 ± 4.1 (2.0 – 
17.5) 
n. s. 
V10Gy (%) 18.3 ± 10.1 (6.8 – 43.6) 18.5 ± 10.2 (6.8 – 
44.0) 
n. s. 
MLD (Gy) 5.6 ± 2.5 (2.4 – 10.9) 5.5 ± 2.5 (2.3 – 
10.9) 
n. s. 
 
Dose to the bronchus did not change significantly between clinical VMAT and 
simulated VMAT plans. However, the largest increase in maximal dose to bronchus was 
3.7 Gy for the example patient shown in Figure 3.7, although still acceptable per RTOG-
0813 protocol.25 Figure 3.8 shows the DVH associated with this patient. 
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Figure 3.7: Example dose distribution for Clinical VMAT vs. Simulated VMAT. 
Coronal view of the isodose distribution is shown for the clinical VMAT plan (left panel) 
and the simulated VMAT plan (right panel), showing the significant loss of target coverage 
(see higher isodose lines with respect to both PTVs). The single‐isocenter location is shown 
by the cross‐hair. For this patient, the bronchus dose increased by 3.7 Gy with simulated 
VMAT whereas the maximal rib dose was decreased by 5.8 Gy. 
Figure 3.8: Dose volume histogram for the example patient. 
The vertical black arrow shows the original planned coverage for both PTV1 (orange) and 
PTV2 (pink). Squares represent the clinical VMAT plan and triangles represent the 
simulated VMAT plan. Shown are the GTVs (red), total lung (brown), ribs (light blue), 
bronchus (cyan), and spinal cord (yellow). The right PTV1 (6.5 cc) and the left PTV2 (18.0 
cc) lost 37.2% and 26.5% coverage, respectively, compared to the original clinical 95% 
PTV coverage of both targets. A small loss of GTV coverage was seen with the simulated 
VMAT plan. 
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3.4 Discussion 
A novel and clinically useful tool was developed to simulate and quantify the 
dosimetric effects of interfraction set up errors in the case of synchronous multiple lesions 
treated via a single-isocenter VMAT lung SBRT. After applying clinically observable pre-
treatment cone beam CT random translational shifts of ± 5 mm and rotational errors of ± 
2° in each direction, dramatic loss of PTV coverage was observed with an average relative 
dose error of 27.4 ± 14.6% (up to 71.7% in some cases) (p < 0.001). Smaller tumors (< 10 
cc) exhibited the greatest PTV coverage loss with random rotations and translations at 39.8 
± 18.3% and 19.8 ± 6.1% for < 10 cc and ≥ 10 cc, respectively. Overall, the GTV dose 
error was less than 1%, on average, but for smaller target sizes was up to -12.3% (p = 0.02). 
Major dosimetric differences were observed in loss of target conformity (p < 0.001) and 
gradient index (p < 0.001), negatively affecting the steep dose gradient desired in SBRT 
treatments. The change in dose to most normal tissues was statistically insignificant and 
probably clinically unimportant, unless critical structures are abutting the target or if re-
irradiation is being considered. In this 6DoF simulation, there was no clear trend of PTV 
coverage loss as a function of distance to isocenter. This is likely due to changing depths 
and SSD affecting the dose calculation rather than the dose just being shifted in the 
patient’s heterogeneous anatomy. Also effecting this trend are randomly generated 
clinically realistic translational errors of ±5mm (in each direction) dominating the small 
but clinically observed rotational error of ±2° (in each direction) or could be due to the vast 
array of PTV sizes obscuring the coverage loss. This is consistent with previously 
published spine SBRT treatment data.32 For instance, Wang et al from MD Anderson 
Cancer Center demonstrated that dosimetric effects from isocenter translational 
displacement of 1-3 mm were more severe than that from patient rotations of 1-3o. 
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Although their study has shown the results of setup uncertainties in the case of a single 
spine lesion treated with an isocenter at the center of the target, a 2-mm translational set up 
error resulted in clinically significant loss of target coverage.  
Using a total of 124 patients with 159 pulmonary lesions treated with variable 
fractionation schemes of SBRT, Guckenberger et al demonstrated that doses of greater than 
100 Gy BED10 to the CTV based on 4D-CT dose calculation resulted in excellent tumor 
local control rates (90% at 3 years).19 Their CTV was generated in the CT pulmonary 
window and the ITV was the sum of the CTV positions in inhalation and exhalation, similar 
to our GTV volume. In this study, the BED10 for the GTV was calculated utilizing the 
minimum dose received by the GTV, whereas the BED10 for the PTV was calculated using 
the dose covering 95% of the PTV volume as described above. We have demonstrated that 
due to residual set up errors, for all patients receiving 50 Gy in 5 fractions, any loss in PTV 
coverage resulted in a BED10 < 100 Gy (p < 0.001) (see Figure 3.6, left panel). For one 
patient, the BED10 for a GTV was only 83.0 Gy. However, for the majority of cases the 
GTV BED10 was still > 100 Gy, suggesting that acceptable tumor local-control is likely. 
For the five patients who had an ITV, all received a prescription dose of 50Gy in 5 
fractions. For these patient’s, three had ITV which received a minimum dose less than 
50Gy and thus did not achieve a BED10 of >100Gy. In the case of the low BED10, whether 
5 mm margin around the GTV is sufficient or not to achieve > 100 Gy BED10 to the GTV 
in this setting merits further investigation. On the other hand, these results suggest that the 
dosing scheme of 54 Gy in 3 fractions always maintains a high BED10 (> 100 Gy) to the 
both PTV and GTV even with simulated set up errors for a single-isocenter/multiple lesions 
VMAT. Therefore, while there was under dosing of the PTV and GTV, it still resulted in a 
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BED >100Gy, implying that this dose and fractionation regimen is the regimen of choice. 
However, if the tumor is near critical structures and warrants 5 treatments, a higher dose 
per day (such as 11-12 Gy for 5 fractions as seen in the RTOG 0813 trial) can be 
considered.  
For many patients, remaining in the treatment position for long periods may be 
uncomfortable and result in intrafraction motion, causing the desire for faster yet effective 
treatment plans. Bissonnette et al demonstrated that spatial errors, although typically small 
in lung SBRT, could be larger with longer treatment times.26 A study by Hoogeman et al 
reported that intrafraction setup errors will increase linearly with treatment time, giving 
incentive to decrease the treatment time for single-isocenter multi/lesions VMAT.27 
Although this simulation study does not account for intrafraction set up errors, this 
consideration would increase uncertainty. Treating patients faster with a single-isocenter 
VMAT plan could minimize intrafraction patient motion errors and improve patient 
comfort. 
Despite growing interest in single-isocenter/multiple-lesion VMAT lung SBRT 
treatments, difficulties due to daily patient set up errors have been described. When treating 
multiple lesions with a single-isocenter VMAT plan, a physician has the task of lining up 
all the lesions on a daily cone beam CT (CBCT) images. It has been reported that boney 
anatomy cannot be used as a surrogate for soft tissue matching for lung SBRT treatment.28 
A clinical study by Trager et al demonstrated that when two lesions share a same isocenter, 
approximately 30% of the time both lesions do not line up correctly in a single CBCT 
images.29 Thus, the physician is faced with a dilemma: what to do if the lesions do not line 
up correctly? The first option would be to align the lesions as best as possible, potentially 
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“splitting-the-difference” if the differences are small and clinically acceptable. The second 
option would be to reposition the patient, repeat the CBCT scan and realign the lesions 
again. If, once again, the lesions do not line up properly the treating physician may need to 
abandon the treatment and either re-plan or try again. This can lead to delays in providing 
appropriate treatment, in addition to adding stress to the SBRT team and slowing down the 
clinic workflow. Quan et al  described the feasibility of treating ≥ 2 lesions with VMAT or 
intensity-modulated radiosurgery (IMRS) and suggested that if all the lesions do not match 
up correctly on the daily pre-treatment CBCT the only option is to abandon the SBRT 
treatment.30 Although aforementioned studies have shown the results of setup uncertainties 
in the case of a single-lesion SBRT treated with an isocenter at the center of the target, the 
authors believe that this is the first study to report the results of patient misalignment for 
extracranial single-isocenter/multi-lesion lung SBRT. Similarly, Clark et al demonstrated 
the dosimetric impact of rotational setup errors for single-isocenter/multi-target VMAT 
SRS to multiple brain metastases using a “third party” software.31 It was reported that 
minimizing rotational setup errors was essential for adequate target coverage, even more 
so for small lesions in the brain and lesions far from the isocenter location. This study 
found that with even 2° rotations in all directions could result in an inadequate PTV target 
coverage with an average of 89.4 ± 10.6%, up to 100% in some cases, however the study 
did not consider the translational set up errors. This current study does not use a “third 
party” software but rather a novel tool to preserve all treatment planning parameters 
including planning CT images and structure contours in Eclipse TPS, therefore introducing 
no additional sources of errors. This tool can be used for both extracranial multi-lesion and 
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single-lesion SBRT or intracranial SRS for multiple or single-lesion treatment, as needed. 
As demonstrated, imperfect patient setup resulted in an unacceptable target coverage loss.  
To minimize this potential loss of target coverage due to set up errors and still 
allowing for a fast SBRT treatment of multiple lung lesions, ongoing research includes 
developing a novel method utilizing a single-isocenter placed at patient’s midline and 
allowing for partial arcs to deliver dose to individual tumors. To minimize setup 
uncertainties, each plan can be re-optimized separately while sharing the same isocenter. 
This allows a SBRT plan to be created for each tumor, while allowing both tumors to be 
treated sequentially during the same session with soft tissue alinement one at a time while 
reducing chance of a geometric miss due to residual setup uncertainties. Placement of a 
single-isocenter at patient’s mediastinum will avoid potential patient collisions and provide 
greater degree of non-coplanar arcs geometry. It will eliminate the need of additional couch 
moments during CBCT imaging (couch centering is required for Varian Linac for lateral 
offsets of > 5 cm, potentially introducing an additional source of error) and minimize the 
need for therapists to enter the treatment room for multiple couch positions.  
 
3.5 Conclusion 
A novel and simple method for demonstrating isocenter misalignment in six 
dimensions and the resulting dosimetric impact for single-isocenter VMAT lung SBRT 
plans for two lesions has been presented. Clinically representative patient setup errors may 
result in large deviations (up to 72% loss) from planned target coverage. Smaller targets 
show the largest deviation from planned coverage including delivering < 100 Gy BED10 
to some targets. Small misalignments can result in substantial decrement in dose gradient 
indicative of SBRT and significantly increase the intermediate dose-spillage. When 
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treating small lesions synchronously with a single-isocenter VMAT lung SBRT plan, 
alternative treatment planning strategies should be explored to minimize the likelihood of 
a geometric miss. 
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CHAPTER 4. A NOVEL RESTRICTED SINGLE-ISOCENTER STEREOTACTIC 
BODY RADIOTHERAPY (RESIST) METHOD FOR SYNCHRONOUS 
MULTIPLE LUNG LESIONS TO MINIMIZE SETUP UNCERTAINTIES 
The following chapter has been adapted from a manuscript currently under review 
for publication: Lana Sanford Critchfield, Mark Bernard, Marcus Randall, Ronald 
McGarry, Damodar Pokhrel, “A Novel Restricted Single-Isocenter Stereotactic Body 
Radiotherapy (RESIST) Method for Synchronous Multiple Lung Lesions to Minimize 
Setup Uncertainties”, J Appl Clin Med Phys, August 8, 2020. 
Abstract 
Treating multiple lung lesions synchronously using a single-isocenter volumetric 
modulated arc therapy (VMAT) stereotactic body radiation therapy (SBRT) plan can 
improve treatment efficiency and patient compliance. However, due to set up uncertainty, 
aligning multiple lung tumors on a single daily cone beam CT (CBCT) image has shown 
clinically unacceptable loss of target(s) coverage. Herein, we propose RESIST, an 
alternative treatment that mitigates setup uncertainties. Twenty-one patients with two lung 
lesions were treated with single-isocenter VMAT-SBRT using a 6MV-FFF beam to 54 Gy 
in 3 fractions (n=7) or 50 Gy in 5 fractions (n=14) prescribed to 70-80% isodose line. To 
minimize setup uncertainties, each plan was re-planned using a Restricted Single-Isocenter 
Stereotactic Body Radiotherapy (RESIST) method, utilizing a single-isocenter placed at 
the mediastinum. It allows for an individual plan to be created for each tumor, using the 
first plan as the base-dose for the second plan, while still allowing both tumors to be treated 
in the same session. The technique uses novel features in Eclipse, including dynamic 
conformal arc (DCA)-based dose and aperture shape controller before each VMAT 
optimization. RESIST plans provided better target dose conformity and gradient indices 
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and lower dose to adjacent critical organs. Using RESIST to treat synchronous lung lesions 
with VMAT-SBRT significantly reduces plan complexity, as demonstrated by smaller 
beam modulation factors, without unreasonably increasing treatment time. RESIST 
reduces the chance of a geometric miss by allowing CBCT matching of one tumor at a 
time. Placement of isocenter at the mediastinum avoids potential patient/gantry collisions, 
provides greater flexibility of non-coplanar arcs and eliminates the need for multiple couch 
movements during CBCT imaging. Efficacy of RESIST has been demonstrated for two 
lesions and can potentially be used for more. Clinical implementation of this technique is 
ongoing. 
 
4.1 Introduction 
The high doses per fraction and complexity associated with lung SBRT leads to 
long treatment times that are further magnified for patients with multiple synchronous lung 
lesions.1 Patients may be uncomfortable in the treatment position and not able to maintain 
it for long treatment times, especially elderly patients and those with multiple 
comorbidities.2 Furthermore, longer SBRT times have been associated with greater 
intrafraction motion errors thus degrading the treatment accuracy.3 The desire to treat 
multiple lung lesions quickly and efficiently with SBRT has led investigators to study 
synchronous VMAT treatments.4-8 These fast treatments employ a single-isocenter shared 
between multiple lesions and high dose rate flattening filter free (FFF) beams, which 
reduces out of field dose and provides better dose coverage at tumor-lung interface 
compared to standard flattened beams.9-11 To further reduce treatment time and plan 
complexity, tools like dynamic conformal arc (DCA), aperture shape controller (ASC), and 
photon optimizer (PO) MLC algorithm are beginning to be utilized.12-14 Reduction of plan 
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complexity can reduce MLC positioning errors, resulting in more accurate dose delivery 
with the additional benefit of decreasing treatment time. However, with the complexity of 
single-isocenter/multiple lesion SBRT treatment plans and the vast array of planning 
options available, consistency in plan quality and treatment delivery efficiency may prove 
problematic. Therefore, a robust treatment planning method for single-isocenter/multiple 
lesion lung SBRT is needed. 
Image-guidance procedures such as CBCT scans prior to treatment have become 
standard of care for lung SBRT. It has been demonstrated that bony anatomy cannot be 
used as a surrogate for tumor-to-tumor matching for lung SBRT.15 Due to tumor motion 
and possible tumor deformation, aligning multiple lung tumors using a single daily CBCT 
can be difficult and may lead to misalignment with the potential of geometric misses. 
Correcting for setup errors for multiple tumors is improved when utilizing a six-degree-of-
freedom (6DOF) couch.16 Previously demonstrated are potential large target coverage 
losses (up to 72% loss from the prescribed dose) associated with small setup errors in 
single-isocenter/multiple lesion lung SBRT treatments using a single daily CBCT.17 
Dosimetric errors were the largest for small lesions. These errors are likely with clinics 
inexperienced with multi-lesion SBRT. Therefore, creation of a robust SBRT treatment 
approach for synchronous multiple lung lesions that decreases the difficulty of patient setup 
and minimizes setup errors while still maintaining fast treatment times is a major goal. 
Herein, we have developed a novel Restricted Single-Isocenter Stereotactic Body 
Radiotherapy (RESIST) method to minimize setup uncertainties and simplify synchronous 
multiple lesion treatments. RESIST used for multiple lung lesions improves target 
localization by matching tumor-to-tumor, provides better target conformity and gradient 
64 
 
indices and reduces doses to organs-at-risk (OAR), while improving treatment times from 
traditional lung SBRT. The RESIST method presented here will guide planners to use the 
optimal treatment geometry and planning options and allow more treatment flexibility for 
physicians and therapists. This study aims to compare plan quality and treatment delivery 
parameters for RESIST with single-isocenter/multiple lesion VMAT lung SBRT plans.  
 
4.2 Materials and Methods 
After obtaining Institutional Review Board Approval, 21 patients with two 
synchronous lung tumors who underwent a single-isocenter VMAT lung SBRT treatment 
of 54 Gy in 3 fractions (n = 7) or 50 Gy in 5 fractions (n = 14) in our clinic were included 
in this study.  
 
4.2.1 Patient Setup and Target Delineation 
Patients were immobilized with the Body Pro-LokTM SBRT system (CIVCO, 
Orange City, IA) in the supine position with arms up. Patients received a free-breathing 
simulation CT scan on a GE Lightspeed 16 slice CT scanner (General Electric Medical 
Systems, Waukesha, WI) with 512 × 512 pixel image size and 2.5 mm slice thickness in 
the axial helical mode. Abdominal compression was employed for most patients or a 4D-
CT scan was obtained, utilizing Varian RPM system (version 1.7). Simulation images were 
imported into Eclipse Treatment Planning System (TPS, Version 15.6, Varian Medical 
Systems, Palo Alto, CA). Gross tumor volumes (GTVs) were contoured based on the 
observable tumor mass from the free-breathing CT or, if a 4D-CT was obtained, internal 
target volumes (ITVs equal to GTVs) were contoured based on maximum intensity 
projection (MIP) registered with the planning CT images. A planning target volume (PTV) 
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was created by expanding the GTV by 10 mm in the superior-inferior direction and 5 mm 
in the lateral direction (free-breathing CT) or with a uniform 5 mm margin (4D-CT). 
Critical structures were contoured per RTOG protocol and included uninvolved lung (right, 
left and combined), spinal cord, heart, bronchus, trachea, esophagus, skin and ribs (right, 
left and combined). Table 4.1 summarizes the tumor characteristics for the 21 patients 
included in this study. 
Table 4.1: Main tumor characteristics of the 21 lung SBRT patients included in this 
study. Each patient had 2 tumors. STD = standard deviation. 
Parameters Mean ± STD (range or n = no. of 
patients) 
Tumor 1, PTV1 (cc) 
Tumor 2, PTV2 (cc) 
 23.3 ± 20.6 (5.0 – 80.9) 
25.9 ± 27.5 (6.38 – 137.2) 
Prescribed dose to each lesion 54 Gy in 3 fractions (n = 7) 
50 Gy in 5 fractions (n = 14) 
Tumor location (left/right/bi-lateral lungs) (n = 6 / 3 / 12) 
Uninvolved lung (cc) 3673.8 ± 1012.8 (1892 – 6542) 
 
 
4.2.2 Clinical VMAT Plans 
For each patient, a single-isocenter lung SBRT plan was generated in Eclipse TPS 
for a Truebeam Linac (Varian Medical Systems, Palo Alto, CA) with Millennium 120 
MLC. Plans were VMAT utilizing a 6MV-FFF (1400 MU/min) beams. The isocenter was 
placed approximately between the two tumors. In order to maintain use of the 0.5 cm MLC 
leaves, the maximum distance between the distal edge of the two lesions should be 20 cm, 
although a greater distance is possible but a degradation in plan quality would be observed. 
Collimator angles were manually chosen based on the tumor arrangement to reduce MLC 
leakage dose between each arc along with utilization of the jaw-tracking feature. For 
optimal MLC use, the collimator is rotated such that the tumors are oriented with the y-
jaw. Two to three full arcs (coplanar) were utilized for bilateral lungs tumors and three to 
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five partial non-coplanar arcs, with couch rotations of ± 10° for unilateral lung tumors. 
Doses were 54 Gy or 50 Gy in 3 or 5 fractions, respectively. Both PTVs (PTV 1 and PTV 
2) were planned with the prescription dose at the 70-80% isodose lines and optimized such 
that at least 95% of each PTV received 100% of the prescription dose. The maximum dose 
to each target was planned to fall inside the GTV. Dose was calculated using Boltzmann 
transport based AcurosXB algorithm in Eclipse for heterogeneity corrections and reporting 
dose to medium.18 Although single-isocenter SBRT was designed for synchronous two 
lesions, planning objectives per RTOG protocols were followed.19, 20   
 
4.2.3 RESIST VMAT Plans 
Each patient was re-planned with the new RESIST method. A single-isocenter was 
placed at the patient’s midline. If the lesions shared an axial plane, the isocenter location 
corresponded with that plane. However, if the lesions were axially separated, the isocenter 
location was placed at the mid-plane of the lesions still at midline. Due to the MLC 
overtravel limitations of the Truebeam Linac, the maximum distance between the distal 
edge of each lesion and isocenter in the x-jaw direction is ±14.5 cm. In order to maintain 
use of the 0.5 cm MLC leaves, the maximum distance between the distal edge of each 
lesion and the isocenter in the y-jaw direction is ±10 cm. Collimator angles were manually 
optimized based on PTV shape and offset from one another to reduce leakage dose and to 
ensure the MLC leaves can travel to each PTV. Treatment planning for PTV 1 began by 
deploying 3 partial arcs with 6 MV FFF (1400 MU/min) beam with couch rotations of 0°, 
10°, and 350°. In the Calculation Models tab (in Eclipse TPS), the PO MLC calculation 
options were assigned to select the strength of aperture shape controller (ASC) to be “very 
high” instead of default “low” in the clinical VMAT plans. A few recent studies have 
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shown that utilizing the ASC in DCA-based VMAT can reduce the total number of monitor 
units and reduce plan complexity and improve the plan quality.13, 14 The MLC aperture was 
fit to the first tumor, PTV 1, with a margin of 0.2 cm and dynamic conformal arc (DCA) 
dose was calculated. After the initial DCA dose calculation, VMAT optimization began for 
target coverage to the PTV 1 (and GTV 1) and to spare adjacent normal structures. Jaw 
tracking option was utilized to further reduce leakage dose to uninvolved lung.21 Figure 
4.1 describes the RESIST planning method for synchronous multiple lung SBRT 
treatments.  
Figure 4.1: The proposed RESIST treatment planning workflow for single-
isocenter/multiple-lesions lung SBRT.  
Using RESIST, initially DCA-based dose plan can be used to reduce the modulation 
factor, thus reducing treatment time and the plan complexity. 
 
A separate plan was created for the second tumor, PTV 2, utilizing the same 
isocenter location used in the previous plan for PTV 1. The same steps were followed as 
above, now with the partial arcs being deployed on the PTV 2 side of the patient, which 
may be the same configuration as for PTV 1. Before VMAT optimization, the plan for PTV 
1 was chosen as the base dose plan. This plan was optimized for coverage to PTV 2 (and 
GTV 2) and to spare adjacent critical structures. Once optimized and calculated, the plan 
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sum was created. In the plan sum module, to obtain optimal coverage of both tumors, 
the dose can be re-normalized to account for the dose contribution from one plan to the 
other.  
 
4.2.4 Plan Comparison and Data Analysis 
All plans were compared per RTOG guidelines for each target conformity, tumor 
heterogeneity and intermediate dose-spillage as follows:  
• Conformality Index (CIRTOG): Ratio of prescription isodose volume to the PTV 
volume. Values between 1.0–1.2 are desirable, but values between 1.2–1.5 
would be acceptable per SBRT protocol with minor deviations. Therefore, for 
prescription isodose volume (VRI), 
                                           𝐶𝐶𝐶𝐶𝑅𝑅𝑃𝑃𝑅𝑅𝑅𝑅 =
𝑉𝑉𝑅𝑅𝑃𝑃
𝑃𝑃𝑃𝑃𝑉𝑉
                                                         (4.1) 
• Paddick Conformation Number (PCNPaddick): Determines the overlap of the 
prescription isodose volume and the PTV volume. 22 Ideally, PCN = 1.0 is 
anticipated. For target volume covered by the prescription dose (PIV), and total 
volume covered by the prescription dose (VRI), 
                                                                  𝑃𝑃𝐶𝐶𝐶𝐶𝑃𝑃𝑃𝑃𝐼𝐼𝐼𝐼𝑃𝑃𝑃𝑃𝑃𝑃 =
𝑃𝑃𝑃𝑃𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃
2
(𝑃𝑃𝑃𝑃𝑉𝑉×𝑉𝑉𝑅𝑅𝑃𝑃)
                                       (4.2) 
• Heterogeneity Index (HI): Evaluates the target(s) dose heterogeneity inside the 
each PTV and is given by: 
                                                             𝐻𝐻𝐶𝐶 = 𝐷𝐷𝑀𝑀𝑀𝑀𝑀𝑀
𝑅𝑅𝑅𝑅
                                                                     (4.3)                      
• Gradient Index (GI): Used to evaluate the intermediate dose-spillage and 
calculated as: 
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                                                           𝑅𝑅𝐶𝐶 = 50%𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑉𝑉𝐼𝐼𝑉𝑉𝑉𝑉𝑉𝑉𝐼𝐼
𝑃𝑃𝐼𝐼𝑉𝑉
                                                (4.4) 
• Maximum dose at 2 cm away from the PTV in any direction (D2cm): Acceptable 
values depend on PTV size.  
Doses to OAR that were evaluated included maximum dose to 0.03 cc of ribs, spinal 
cord, heart, bronchial tree, esophagus and skin. Volumetric doses evaluated included dose 
to 1 cc of ribs, 0.35 cc of spinal cord, 15 cc of heart, 4 cc of bronchial tree/trachea, 5 cc of 
esophagus and 10 cc of skin. Lung doses were evaluated using the mean lung dose (MLD) 
and percentage of lung receiving 10 Gy (V10Gy) and 20 Gy (V20Gy) or more. Total 
monitor units (MU), beam modulation factor (MF) and beam on time was recorded. Overall 
treatment time (including CBCT scan time) was estimated between the 2 methods. MF was 
defined as the ratio of total number of MU to the prescription dose in cGy. Data was 
assessed for normality, then either a paired two-tail Student’s t-test (Microsoft Excel, 
Microsoft Corp., Redmond, WA) or a Mann-Whitney test (Minitab, Minitab LLC, 
Chicago, IL) was used to compare the data for the clinical VMAT versus simulated VMAT 
plans for all parameters of target coverage and dose tolerances to OAR. A value of p < 0.05 
was considered statistically significant. 
 
4.3 Results 
4.3.1 Target Coverage and Dose to OAR 
All RESIST plans demonstrated equivalent PTV coverage compared to the clinical 
VMAT plans, but provided better conformity indices, heterogeneity index, gradient index 
and D2cm, as shown in Table 4.2. Overall, the GTV doses were similar except, in some 
cases, the minimum dose to the GTV was improved with RESIST from 91.4% to 96.5% of 
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the prescribed dose. The RESIST plans exhibited RTOG conformity index and PCN values 
closer to unity than the single-isocenter VMAT plans, suggesting that the RESIST method 
can produce more conformal dose distributions than the original clinical method. Gradient 
index (p < 0.001) and maximum dose 2 cm away from the PTV in any direction (p = 0.02) 
were improved significantly with RESIST suggesting less intermediate dose-spillage in the 
uninvolved lung. 
Table 4.2: Analysis of the target coverage of the dosimetric parameters for all 21 lung 
SBRT patients treated with single-isocenter/multiple-lesions VMAT compared to 
RESIST plans. Mean ± STD (range) and p-values were reported. Significant values 
are highlighted in bold. STD = standard deviation. PCN = Paddick Conformation 
Number. CI = conformity index. HI = heterogeneity index. 
Target Parameter Clinical VMAT plans RESIST VMAT 
plans 
p-value 
PTV  
(n = 
42) 
% Vol. 
covered by 
Rx dose (%) 
96.3 ± 1.3 (94.8–99.3) 96.1 ± 0.8 (94.9–98.3) p = 0.1 
CI 1.04 ± 0.05 (0.96–
1.21) 
1.02 ± 0.03 (0.97–
1.09) 
p = 0.003 
PCN 0.88 ± 0.03 (0.81–
0.96) 
0.90 ± 0.03 (0.85–
0.95) 
p < 0.001 
HI 1.21 ± 0.3 (1.13–1.31) 1.19 ± 0.04 (1.11–
1.28) 
p = 0.005 
GI 5.77 ± 2.46 (3.60–
17.6) 
4.92 ± 0.98 (3.45–
8.15) 
p < 0.001 
D2cm (%) 53.3 ± 5.3 (46.5–67.0) 51.6 ± 3.6 (45.0–61.3) p = 0.02 
GTV  
(n = 
42) 
Minimum 
dose (%) 
108.4 ± 4.7 (91.4–
117.3) 
107.5 ± 4.9 (95.6–
117.1) 
p = 0.1 
Maximum 
dose (%) 
120.9 ± 3.6 (113.2–
129.4) 
119.1 ± 3.7 (111.7–
128.1) 
p = 0.001 
Mean dose 
(%) 
114.8 ± 2.8 (110.1–
120.3) 
113.7 ± 3.8 (107.8–
122.6) 
p = 0.04 
 
Table 4.3 shows the dose differences for the OAR between the clinical VMAT and 
RESIST VMAT plans. The average differences between all OAR maximum and 
volumetric doses were positive values, demonstrating that on average RESIST can 
decrease the dose to all OAR. Furthermore, RESIST significantly reduced the uninvolved 
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lung V10Gy by 3.4% (up to 13.9%) and, in all cases, reduced MLD by about 0.7 Gy (up to 
2.0 Gy) and V20Gy by 1.0% (up to 3.2%), on average. On a case-by-case basis, some OAR 
doses slightly increased using the RESIST method shown as negative values (see Table 
4.3). This can be attributed to the fact that for certain tumor arrangements (unilateral lesions 
in the same axial plane), more arcs utilized similar geometry and thus deliver more MU to 
the same organ. However, this increase in dose was minimal, with the biggest difference 
being seen for 1 cc of ribs where one RESIST plan delivered was about 4.0 Gy more than 
the clinical plan, still well below the SBRT protocol limits. For many cases, the decrease 
in OAR dose from the clinical VMAT plan to the RESIST plan was dramatic due to better 
beam geometry. For example, a decrease of 5.8 Gy for the spinal cord maximum is 
observed in an example case. This dose drop can be attributed to optimal arc geometry 
decreasing the need to treat the target through critical structures, such as the spinal cord. 
Similarly, in some instances, the maximal dose to heart and esophagus were decreased by 
up to 7.2 Gy and 9.2 Gy (see Table 4.3), respectively. 
Table 4.3: Evaluation of dose to OAR for all 21 multi-lesions lung SBRT patients for 
both plans. Mean ± SD (range) was reported. SD = standard deviation. MLD = mean 
lung dose. Statistically significant p-values are highlighted in bold. 
Dose to OAR Parameters Difference = Clinical 
minus RESIST plan 
p-value 
Spinal cord (Gy) Dmax 0.73 ± 1.98 (-2.02 – 5.81) p = 0.06 
D0.35cc 0.68 ± 1.8 (-1.97 – 5.07) p = 0.05 
Heart/pericardium 
(Gy) 
Dmax 2.21 ± 2.6 (-1.61 – 7.17) p < 0.001 
D15cc 2.61 ± 1.82 (0.03 – 6.94) p < 0.001 
Esophagus (Gy) Dmax 1.83 ± 2.99 (-1.9 – 9.14) p < 0.001 
D5cc 2.43 ± 2.67 (-0.95 – 7.87) p < 0.001 
Trachea/bronchus 
(Gy) 
Dmax 1.15 ± 2.53 (-2.24 – 6.46) p = 0.03 
D4cc 2.08 ± 2.48 (-1.31 – 6.93) p < 0.001 
Skin (Gy) Dmax 0.32 ± 1.59 (-2.76 – 3.68) p = 0.2 
D10cc 0.88 ± 0.93 (-0.7 – 2.94) p < 0.001 
Ribs (Gy) Dmax 1.58 ± 2.07 (-2.0 – 7.73) p = 0.001 
D1cc 0.13 ± 1.61 (-4.36 – 3.16) p = 0.4 
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Table 4.3 (Continued) 
Uninvolved lung MLD (Gy) 0.65 ± 0.53 (0.01 – 1.96) p < 0.001 
V20Gy (%) 0.99 ± 0.87 (0.03 – 3.14) p < 0.001 
V10Gy (%) 3.43 ± 3.46 (-2.02 – 13.9) p < 0.001 
 
In Figures 4.2 and 4.3, the benefits of RESIST beam geometry are demonstrated. 
With RESIST, because the isocenter is always placed at the patient’s midline, partial arcs 
of 180° arc length are always achievable on the tumor side of the patient. With RESIST, 
highly conformal and much tighter target dose distributions with less 50% isodose spillage 
were achieved (Figure 4.2). RESIST isocenter placement avoids collisions and minimizes 
uninvolved lung dose with local jaw tracking to each tumor one at a time. Smaller jaw 
tracking field sizes are seen with the RESIST plan. Additionally, a significantly lower dose 
to the critical structures including ribs was achieved due to the patient’s midline isocenter 
placement allowing for arcs to be utilized on both sides of the patient (Figure 4.3).  
Figure 4.2: Coronal view for an example clinical plan (left panel) and the RESIST 
plan sum (right panel), each lesion was treated for 50 Gy in 5 fractions synchronously. 
The isocenter placement at the patient’s mediastinum is shown for RESIST, allowing for 
optimal partial non-coplanar arcs to be utilized in both directions, compared to only one 
couch rotation was possible in the clinical plan for this patient due to possible collisions.  
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Figure 4.3: Axial view for the same example patient. 
In the clinical VMAT plan, the isocenter placement restricted dose delivery for the lesion 
in the right lung to be primarily exit dose through the critical structures such as spinal cord, 
esophagus and left lung. The patient midline isocenter placement with RESIST allowed for 
optimal arcs on both sides of the patient, permitting lower OAR doses as well as more 
conformal target dose distribution to each lesion. 
 
Figure 4.4 demonstrates the special case when both lesions are in close proximity 
of one another. Placing the isocenter at patient’s midline allowed for non-coplanar arc 
geometry without risk of patient collision, which was beneficial even in the case like this. 
Because both lesions are planned separately, with RESIST the MLCs are not required to 
move between the lesions and jaw tracking was restricted to one single lesion at a time. 
Thus, the uninvolved lung dose between the lesions was reduced significantly as 
demonstrated by the reduced 50% isodose volume. Likewise, it lowered V20Gy by 1.5%, 
V10Gy by 1.7% and MLD by 0.7 Gy. RESIST significantly improved the GI for both 
targets at 5.2 and 6.3 compared to 12.7 and 17.6 for the original clinical VMAT plan. 
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Figure 4.4: This is an example case of two lesions near one another. 
Each lesion was prescribed 50 Gy in 5 fractions synchronously using a clinical single-
isocenter VMAT plan. Structures contoured include total lung (light blue), heart (blue), 
cord (yellow), ribs (green), and skin (purple), PTVs (orange) and the GTVs (red). A 2 cm 
expansion is contoured around each PTV (brown). RESIST plan sum (right panel) 
demonstrated a highly conformal dose distribution to both lesions with no 50% dose 
bridging between the lesions (see blue dose color wash) 
4.3.2 Treatment Delivery Parameters 
The improvement of treatment delivery efficiency and accuracy is associated with 
Eclipse’s new feature of adjustable aperture shape control priority and the initial DCA-
based dose calculation before the VMAT optimization (Eclipse, Version 15.6). With this 
new feature, less beam modulation through the PTVs was observed thus reducing the 
uncertainty of modeling small-field dosimetry. Total MU per fraction for the RESIST plans 
(2 plans with a single-isocenter placed at patient’s midline) increased by a factor of 1.7 on 
average, compared to single-isocenter clinical VMAT. Although the beam on time is 
increased for the RESIST plans, the average modulation factor for these plans is reduced 
significantly (p < 0.001), as shown in Table 4.4, potentially improving the treatment 
delivery accuracy. 
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Table 4.4: Comparison of average values of treatment delivery parameters (and 
range) between clinical VMAT and RESIST plans for all 21 lung SBRT patients. 
Mean ± SD (range) was reported. SD = standard deviation. Statistically significant p-
values are highlighted in bold. 
Beam delivery 
parameters 
Clinical VMAT RESIST VMAT p-value 
Total MU per 
fraction 
5130 ± 1977 (2784–
10727) 
8793 ± 2572 (5605–
15537) 
p < 0.001 
Modulation factor 
(MF) 
4.2 ± 1.3 (2.8–8.6) 3.5 ± 0.7 (1.9–5.1) p < 0.001 
Beam-on time (min) 3.7 ± 1.4 (2.0–7.7) 6.3 ± 1.8 (4.0–11.1) p = 0.01 
Treatment time 
(min) 
17.7 ± 1.4 (16.0–21.7) 24.3 ± 1.8 (22.0–29.1) p < 0.001 
 
The estimated mean treatment time for both plans (including patient setup, CBCT 
imaging, and tumor matching) was 17.7 minutes for clinical VMAT versus 24.3 minutes 
for RESIST. The estimated time for initial patient setup on the machine is about 10 minutes 
and the estimated time to complete one CBCT is 1 minute followed by another about 3 
minutes for tumor matching and applying shifts. Although the treatment time is longer for 
RESIST when accounting for the possibility of a second CBCT scan and tumor matching, 
there will be reduced geometric uncertainties and reduced likelihood of a geometric miss. 
The RESIST treatments are still reasonably achievable in the standard 30-minute time slot 
usually allotted to treat SBRT patients. As previously demonstrated, small setup errors in 
single-isocenter SBRT treatments to two lesions at the same time could potentially produce 
a large decrement in target coverage if the tumors could not line up correctly on a single 
daily CBCT. These errors could be avoided by setting up and treating one lesion at a time 
using the novel RESIST method.  
4.4 Discussion 
A novel and clinically useful RESIST method for synchronous multiple lung 
lesions that minimizes setup uncertainties is described. Twenty-one patients with two 
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lesions were treated with a single-isocenter VMAT-SBRT plan with the isocenter placed 
between the lesions. Each patient was replanned using the RESIST method with a single 
isocenter placed at the patient’s midline and each tumor was separately optimized in an 
individual plan. Each RESIST plan utilized the same number of arcs, couch rotations, and 
planning selections including the use of DCA-based dose, ASC, PO MLC algorithm and 
advanced AcurosXB dose calculation. RESIST plans exhibited more conformal target dose 
distribution with improved conformity and gradient indices compared to clinical single-
isocenter VMAT plans. Additionally, the average dose to all adjacent critical structures 
was decreased, including the uninvolved lung dose potentially reducing the rate of 
radiation-induced pneumonitis.23 
The average modulation factor for the individual RESIST plans was reduced 
compared to the original clinical plans. This reduction in plan complexity can be attributed 
to the use of an initial DCA-based dose calculation, ASC, and PO MLC algorithm. 
Although multiple studies suggest that interplay effect is minimal in multi-fraction lung 
SBRT treated with VMAT24, 25, reducing plan complexity can also reduce treatment time 
and MLC position errors, improving accurate dose delivery by reducing small-field 
dosimetry errors.26, 27 The RESIST method further improves accurate dose delivery by 
allowing each lesion to be lined up individually during daily pre-treatment CBCT scan. 
Figure 4.5 describes the treatment delivery workflow for the RESIST patients. With the 
current clinical VMAT plan, the physician must line up both lesions on a single CBCT 
scan. If both lesions do not line up, possibly due to tumor deformation or a change in tumor 
motion, the physician must make one of two decisions: they may “split-the-difference" 
between the lesions (which is not recommended), risking target coverage loss due to 
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geometric misalignment, or they may need to setup and re-image the patient again. If they 
opt for the second option and the lesions do not line up, the physician may need to abandon 
the treatment and try again another day or re-plan the treatment thus adding burden to the 
radiation therapists and SBRT team. 
In a study by Quan et al, it was suggested that when treating multiple lesions with 
VMAT or intensity-modulated radiosurgery the event of multiple lesions not lining up 
during pre-treatment imaging would cause the treatment to be abandoned.7 Using the 
RESIST method, if both lesions do not line up during the first daily CBCT the physician 
can choose to line up the first tumor and treat the first plan then repeat the second CBCT, 
match the second tumor and treat the second plan. In between the plans, the therapists do 
not need to enter the room to reposition the patient because the plans share the same 
isocenter and the isocenter placement at patient midline ensures the CBCT will clear the 
patient without applying a couch shift (shift needed for Varian Linac/couch for off-center 
patients > 5 cm laterally). Likewise, the physician can choose to treat only one lesion per 
treatment without causing any error in dose tracking. We have demonstrated that in the 
case of two CBCT scans needed, the treatment still falls within the usually allotted 30-min 
treatment time slot for SBRT patients. In addition to minimizing the potential geometric 
misses, this workflow allows for more flexibility for treating synchronous multiple lung 
SBRT lesions by allowing patients to take breaks in between tumors or allowing physician 
to treat different tumors at different days to manage lung toxicity. 
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Figure 4.5: The proposed RESIST treatment delivery workflow for single-
isocenter/multiple-lesions VMAT lung SBRT. 
The physician has the option to set up all tumors at the same time (left blue box) or match 
one tumor at a time and treat without entering the treatment room for resetting up the patient 
for the second CBCT scan. 
Trager et al from Duke University Medical Center devised a method for mitigating 
setup uncertainties in single-isocenter/multiple lesion SBRT treatments.28 The authors 
determined that approximately 30% of fractions required a correction in order to accurately 
line up both lesions. Their solution to this problem utilized a single-isocenter shared 
between two lesions, but each lesion was optimized with its own arc. The authors also 
identified that beginning each plan with DCA-based dose calculation decreased the plan 
complexity. Although their method is a viable option for minimizing setup uncertainties, 
the study primarily focused on phantom-based plans with only one lung plan demonstrated. 
With only one arc per plan and the use of inferior dose calculation algorithm, Anisotropic 
Analytical Algorithm (Varian Medical Systems, Palo Alto, CA), their method does not take 
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full advantage of the proven benefit of non-coplanar arc geometry and the improved dose 
calculation abilities of AcurosXB.29-31 Furthermore, their method did not provide further 
guidance for treatment planners concerning isocenter placement and clearance issues. In 
contrast, this study has presented a comprehensive treatment planning and more accurate 
delivery approach for the cohort of two lesion lung SBRT patients. This method minimizes 
setup uncertainties, improves target dose conformality, reduces dose to adjacent critical 
structures and reduces plan complexity in addition to simplifying treatment planning and 
treatment delivery. Although, overall treatment time was longer with RESIST method 
compared to clinical VMAT plans, the treatment time using RESIST will still be much 
shorter than utilizing traditional multiple isocenters 3D-conformal or VMAT SBRT 
treatments, robotic CyberKnife treatment to lung lesions (45 minutes for one tumor) or 
SBRT treatments on Tomotherapy unit (40-50 minutes).32-34 Future work includes clinical 
implementation of RESIST technique including more than two tumors in the same session. 
Moreover, to further simplify the RESIST planning process, the creation of a template 
treatment plan module in Eclipse TPS is ongoing. This template treatment plan will further 
simplify the treatment planning process and improve delivery accuracy of RESIST. This 
method can be expanded further to other treatment sites such as multiple lesion liver SBRT 
or abdominal and pelvic node SBRT. 
4.5 Conclusion  
 
Using RESIST to treat synchronous lung lesions with VMAT-SBRT can 
significantly improve target dose conformality, reduce dose to adjacent OAR while 
reducing the chance of a geometric miss due to setup uncertainties by allowing for 
individual tumor matching. Placement of single-isocenter at patient’s mediastinum will 
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avoid potential patient’s collision with the gantry head, provide greater degrees of non-
coplanar arcs and eliminate the need for multiple couch movements during CBCT imaging 
for off-center lesions. RESIST has been demonstrated for two tumors but can be used for 
more. Further clinical validation of this novel technique is ongoing. 
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CHAPTER 5. AUTOMATION AND INTEGRATION OF RESTRICTED SINGLE-
ISOCENTER STEREOTACTIC BODY RADIOTHERAPY (RESIST) METHOD 
FOR SYNCHRONOUS MULTIPLE LUNG LESIONS 
The following chapter has been adapted from a manuscript currently under review 
for publication: Lana Sanford Critchfield, Justin Visak, Mark Bernard, Marcus Randall, 
Ronald McGarry, Damodar Pokhrel, “Automation and Integration of Restricted Single-
Isocenter Stereotactic Body Radiotherapy (RESIST) Method for Synchronous Multiple 
Lung Lesions”, J Appl Clin Med Phys, September 29, 2020. 
Abstract 
Synchronous treatment of two lung lesions using a single-isocenter volumetric 
modulated arc therapy (VMAT) stereotactic body radiation therapy (SBRT) plan can 
decrease treatment time and reduce the impact of intrafraction motion. However, alignment 
on a single cone beam CT (CBCT) can prove difficult and may lead to setup errors and 
unacceptable target coverage loss. A Restricted Single-Isocenter Stereotactic Body 
Radiotherapy (RESIST) method was created to minimize setup uncertainties and provide 
treatment delivery flexibility. RESIST utilizes a single isocenter placed at midline and 
allows both lesions to be planned separately but treated in the same session. Herein is 
described a process of automation for the RESIST method. Automation of RESIST 
significantly reduced treatment planning time while maintaining the benefits of RESIST. 
To demonstrate feasibility, ten patients with two lung lesions previously treated with 
single-isocenter clinical VMAT plan were replanned manually with RESIST (m-RESIST) 
and with automated RESIST (a-RESIST). The a-RESIST method automatically sets 
isocenter, creates beam geometry, choses appropriate dose calculation algorithms, and 
performs VMAT optimization using an in-house trained knowledge-based planning model 
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for lung SBRT. Both m-RESIST and a-RESIST showed lower dose to normal tissues 
compared to manually planned clinical VMAT although a-RESIST provided slightly 
inferior, but still clinically acceptable, dose conformity and gradient indices. However, a-
RESIST significantly reduced the planning time to less than 20 minutes and provided a 
higher dose to the lung tumors. The a-RESIST method provides guidance for inexperienced 
planners by standardizing beam geometry and plan optimization using DVH estimates. It 
produces clinically acceptable two lesion VMAT lung SBRT plans efficiently. Further 
development of a-RESIST for more than two lung lesions and refining this approach for 
extracranial oligometastastic abdominal/pelvic SBRT, including development of simulated 
collision detection, merits future investigation. 
 
5.1 Introduction 
Stereotactic body radiation therapy (SBRT) of synchronous multiple primary or 
metastatic lung lesions can result in excessively long treatment times for patients and busy 
clinics. To alleviate this, a single-isocenter intensity modulated radiation therapy (IMRT) 
or volumetric modulated arc therapy (VMAT) SBRT plan is a feasible treatment option for 
patients presenting with synchronous multiple metastatic or primary lung lesions. 1-5 SBRT 
of two lung lesions with a single-isocenter VMAT plan decreases treatment delivery time, 
increases patient comfort, and reduces the chance of intrafraction tumor motion errors.5 
However, small setup errors may occur due to the difficulties of multiple lung lesion 
alignment on a single cone beam CT (CBCT) scan. These small setup errors may lead to 
unacceptable loss in target coverage due to lung heterogeneities and the steep dose 
gradients obtained in SBRT. 6 Thus, a Restricted Single-Isocenter Stereotactic Body 
Radiotherapy (RESIST) method was developed to minimize the problems associated with 
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single-isocenter VMAT lung SBRT (e.g., setup errors, collision issues). 7 It has been 
reported that patient outcome is related to a clinic’s experience in delivery of SBRT.8 There 
are no definitive planning guidelines for inexperienced clinics in the treatment of multiple 
lesion lung SBRT who wish to treat their patients efficiently and accurately.  
Recently, investigators have presented work on the use of automation for 
generating lung SBRT treatment plans using a knowledge-based planning (KBP) approach 
with dose volume histogram estimates via RapidPlan (RP) modeling (Varian Medical 
Systems, Palo Alto CA).9-11 KBP models can generate plans quickly and improve plan 
quality and consistency by reducing inter-planner variability. These models are trained 
using previously treated high quality treatment plans and provide a good starting point for 
subsequent plan optimization. However, there has yet to be a KBP model to automate 
treatment planning for multi-lesion lung SBRT. In order to guide planners in generating 
single-isocenter/two-lesion VMAT lung SBRT plans, an automated treatment planning 
routine (a-RESIST) has been developed using the RESIST planning geometry, which is 
further optimized using an in-house trained KBP lung SBRT model. 10 This report aims to 
demonstrate the feasibility of the a-RESIST planning technique and its ability to assist 
planners in improving planning efficiency, consistency and accuracy. Further, this report 
also provides guidance for automating treatments for fast and effective synchronous 
multiple lesion lung SBRT. 
 
5.2 Materials and Methods 
After obtaining institutional review board approval, ten patients were selected with 
two lung tumors each who were previously treated to 50 Gy in 5 fractions using a single-
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isocenter VMAT lung SBRT. For each patient, both lesions were treated at the same time 
every other day.  
 
5.2.1 CT Simulation and Contouring  
Patients were immobilized with the Body Pro-LokTM SBRT system (CIVCO, 
Orange City, IA) in the supine position with arms up. A simulation CT scan was obtained 
on a GE Lightspeed 16 slice CT scanner (General Electric Medical Systems, Waukesha, 
WI) with 512 × 512 pixel image size and 2.5 mm slice thickness in the axial helical mode. 
For respiratory control, most patients tolerated abdominal compression, if not a 4D-CT 
scan was obtained by utilizing Varian RPM system (version 1.7). Images were imported 
into the Eclipse Treatment Planning System (TPS, Version 15.6, Varian Medical Systems, 
Palo Alto, CA).12 Gross tumor volumes (GTVs) were contoured based on the observable 
tumor mass. If a 4D-CT was obtained, internal target volumes (ITVs) were contoured based 
on maximum intensity projection (MIP) co-registered with the free breathing planning CT 
images. A planning target volume (PTV) was created by expanding the GTV by 10 mm in 
the superior-inferior direction and 5 mm in the lateral directions (abdominal compression) 
or expanding the ITV with a uniform 5 mm margin (4D-CT). Critical structures were 
contoured, including normal lung (right, left and combined), spinal cord, heart, bronchus, 
trachea, esophagus, skin and individual ribs (right, left and combined) per RTOG 
requirements.13, 14 Table 5.1 summarizes the tumor characteristics and tumor distance to 
isocenter for the ten multi-lesions lung SBRT patients included. Distance to isocenter was 
calculated by finding the Cartesian coordinates of the PTV geometric center and 
determining the Euclidian 3D distance with the isocenter coordinates for each plan. 
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Table 5.1: Main tumor characteristics of the 10 lung SBRT patients included in this 
study. Each patient had 2 tumors. STD = standard deviation. 
Parameters and plans Mean ± STD (range or n = no. of 
patients) 
Tumor 1, PTV1 (cc) 
Tumor 2, PTV2 (cc) 
 21.35 ± 17.16 (6.5 – 69.6) 
21.95 ± 13.06 (6.38 – 40.9) 
Prescribed dose to each lesion 50 Gy in 5 fractions  
Tumor location (left/right/bi-lateral lungs) (n = 4 / 1 / 5) 
Normal lung (cc) 3837.3 ± 1171.2 (2041 – 6542) 
Isocenter to tumor distance 
(cm) 
Clinical plans 5.5 ± 2.3 (2.4 – 9.2) 
m-RESIST 
plans 
7.4 ± 2.0 (3.2 – 11.3) 
a-RESIST 
plans 
8.1 ± 2.1 (4.5 – 10.9) 
 
5.2.2 Clinical VMAT Plans 
A single-isocenter lung SBRT plan was generated in Eclipse TPS to be treated with 
a Truebeam Linac (Varian Medical Systems, Palo Alto, CA) with the Millennium 120 
MLC. All plans were VMAT utilizing 6MV‐FFF (1400 MU/min) beams. The isocenter 
was placed approximately between the two tumors. For patients who presented with 
bilateral tumors or select unilateral tumors, two to three full coplanar arcs were used for 
treatment. For the remaining unilateral cases, three to five partial coplanner or non-
coplanar arcs with couch rotations up to ± 10° were utilized (planner preference). 
Collimator angles were manually chosen to reduce the MLC leakage dose between each 
arc with the jaw-tracking feature enabled.16 Dose was 50 Gy in 5 fractions for all patients. 
Target naming convention (PTV1 or PTV2) was chosen by the treating physician. Both 
PTVs were planned with dose prescribed to the 70-80% isodose lines and optimized such 
that at least 95% of each PTV received 100% of the prescription dose. The maximum dose 
to each target was planned to fall inside the GTV. Dose was calculated using the Boltzmann 
transport based AcurosXB algorithm in Eclipse with heterogeneity corrections with a 1.25 
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mm calculation grid size (CGS).12 Reporting dose to medium and photon optimizer (PO) 
MLC algorithm was used. Although single-isocenter SBRT was designed for synchronous 
treatment of two lesions, planning objectives per RTOG protocols and NRG-BR001 were 
utilized for the organs-at-risk (OAR).1, 13-15 Each patient was treated every other day with 
the VMAT planning technique using an in-house CBCT-guided lung SBRT protocol.  
 
5.2.3 m-RESIST VMAT Plans 
Each patient’s clinical treatment plan was replanned using the manual RESIST (m-
RESIST) method. The m-RESIST method places isocenter at the patient’s midline and both 
tumors share the treatment isocenter. If the lesions are separated in the x-direction, the 
isocenter is placed approximately between the lesions in the mid-coronal plane of the 
patient. A separate plan is made for PTV1 and PTV2. Each plan has 3 partial non-coplanar 
VMAT arcs with a 6 MV FFF (1400 MU/min) beam deployed on the tumor side of the 
patient. Couch rotations were 0°, 10° and 350° for each beam, respectively. Collimator 
angles were offset by 30° to reduce leakage dose in the same plane and were chosen to 
ensure the MLCs can travel to the PTV locations. The aperture shape controller (ACS) in 
the PO MLC algorithm was set to ‘very high’ in order to reduce the total number of monitor 
units, reduce plan complexity and improve plan quality.17, 18 The m-RESIST plans were 
created by fitting the MLCs to PTV1 and then calculating the dynamic conformal arc 
(DCA) dose for the respective plan. Next, standard manual VMAT optimization began for 
PTV1 and GTV1 coverage. The jaw tracking option was employed to reduce leakage dose 
to normal lung as described above.16 Once dose calculation was complete, the plan for 
PTV1 was used as a base-dose plan before VMAT optimization in the plan for PTV2. The 
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PTV2 plan was optimized for coverage to PTV2 and GTV2 and to spare the OAR. Once 
optimized and calculated, a m-RESIST plan summation was created with both plans and 
re-normalized to account for contribution from each plan. The plans were then evaluated 
per lung SBRT protocols. 
 
5.2.4 a-RESIST VMAT Plans 
Varian Eclipse Scripting Application Programming Interface (ESAPI, Version 
15.5) allows for integration of writable scripts and supports the automation of SBRT 
plans.19 A script (a-RESIST) was developed using Microsoft Visual Studio written in C# 
with guidance from the Varian APIs handbook. 20 Running the script in external beam 
planning will begin the a-RESIST treatment planning method and selects the appropriate 
patient’s planning CT dataset and structure set. Utilizing a-RESIST automation requires 
precise structure naming convention chosen based on institution standards (such as PTV1, 
PTV2, Lt ribs etc.). The a-RESIST automation routine includes the following: 
1. Creation of treatment course AutoPlan RESIST and creation of two plans: 
RESIST PTV1 and RESIST PTV2.  
2. Placement of single treatment isocenter with x- and y- based on the 
coordinates of the spinal cord contour and z- being the axial plane between 
the two PTVs.  
3. Selection of machine (Truebeam Linac), energy (6MV FFF), VMAT arc 
geometry, and dose rate (1400 MU/min). 
4. Creation of 3 partial arcs from 0° to 180° (CW and CCW direction) on the 
PTV side of the patient. 
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5. Offset collimator angles based on PTVs distance to isocenter to allow for 
optimal MLC travel distance to PTVs. 
6. Selection of appropriate dose calculation algorithms (AcurosXB, PO, 
VMAT optimization, DVH Estimates algorithm). 
7. Application of normal tissue objective and jaw tracking to be used in 
optimization. 
8. Optimization of plans using an in-house KBP model for lung SBRT.11  
Figure 5.1 demonstrates the automated (dashed box) and user input sections of the 
planning workflow for a-RESIST. After dose calculation of the first plan (RESIST PTV1), 
this plan is chosen as the base-dose plan for the second plan (RESIST PTV2). The second 
plan is optimized and dose is calculated. A plan summation is then created by the user and 
plans are renormalized (if needed) together such that 95% of each PTV receives 100% of 
the prescription dose. The user can adjust the plans from there, further re-optimizing the 
plans (if needed) including adjusting the beam geometry for better coverage or normal 
tissue sparing.  
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Figure 5.1: The a-RESIST treatment planning workflow for a single-isocenter/two 
lesions VMAT lung SBRT. 
The selections in the dashed blue box were deployed by the automated treatment planning 
script. Utilizing a-RESIST reduces the treatment planning time and ensures standardized 
plans for synchronous multi-lesion lung SBRT.  
 
5.2.5 Plan Comparison and Data Analysis 
Plans were compared per RTOG guidelines for target conformity (CI), tumor dose 
heterogeneity (HI), gradient index (GI) and intermediate dose spillage at 2 cm away in any 
direction for each target (D2cm).1,5,14,15Additionally, Paddick conformation number (PCN) 
was calculated for each target.21 Minimum, maximum and mean dose to each GTV was 
assessed. Doses to OAR that were evaluated included maximum dose to 0.03 cc of ribs, 
spinal cord, heart, bronchial tree, esophagus and skin. Volumetric doses to OAR’s were 
also evaluated for 1 cc of ribs, 0.35 cc of spinal cord, 15 cc of heart, 4 cc of bronchial 
tree/trachea, 5 cc of esophagus and 10 cc of skin. Lung doses were evaluated for percentage 
of normal lung receiving 10 Gy (V10Gy) and 20 Gy (V20Gy) or more and the mean lung 
dose (MLD). Moreover, overall treatment planning time was estimated for all 3 plans. 
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Statistical analysis was performed using Microsoft Excel (Microsoft Corp, Redmond WA) 
program. Mean, standard deviation (STD) and range values for each of the dose metrics 
were compared for all 3 plans. 
 
5.3 Results 
5.3.1 Target Coverage and Dose to OAR 
All a-RESIST plans demonstrated acceptable target coverage per SBRT protocols, 
as shown in Table 5.2. For similar target coverage, a-RESIST plans provided slightly 
inferior CI and D2cm compared to both clinical VMAT and m-RESIST plans; however, 
GI was slightly better with a-RESIST plan. The large GI values reported for clinical VMAT 
are due to dose bridging between lesions that is eliminated using RESIST methods. 
Likewise, a-RESIST show inferior PCN compared to m-RESIST plan. These discrepancies 
are likely attributed to the use of KBP model generating a-RESIST plans slightly inferior 
to manually optimized treatment plans. This slight degradation can be accounted for given 
that the KBP model was originally developed for single-lesion SBRT plans, i.e. the input 
data in the model did not include plans that included a base dose thus affecting model 
performance. However, the KBP model helped to produce a-RESIST plans with higher 
GTV minimum, maximum and mean doses compared to the other planning strategies (see 
Table 5.2). This dose escalation is desirable in SBRT since normal tissue dosing was still 
acceptable. For instance, the mean GTV dose for a-RESIST was 7% and 6% higher (up to 
3.5 Gy) compared to m-RESIST and clinical VMAT plans, respectively.  
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Table 5.2: Analysis of the target coverage of the dosimetric parameters for 10 lung 
SBRT patients. Mean ± STD (range). STD = standard deviation. PCN = Paddick 
Conformation Number. CI = conformity index. HI = heterogeneity index. n = number 
of targets. 
Target Parameter Clinical VMAT m-RESIST a-RESIST 
PTV  
(n = 20) 
% Vol. 
covered by 
 Rx dose 
(%) 
96.2 ± 1.0 (94.8–
99.0) 
95.8 ± 0.4 (95.1–
96.8) 
95.9 ± 0.7 (95.2–
98.1) 
CI 1.04 ± 0.05 (0.97–
1.21) 
1.02 ± 0.03 
(0.97–1.09) 
1.06 ± 0.03 
(0.99–1.16) 
PCN 0.88 ± 0.03 (0.81–
0.94) 
0.90 ± 0.02 
(0.85–0.93) 
0.88± 0.02 
(0.80–0.92) 
HI 1.21 ± 0.3 (1.15–
1.26) 
1.19 ± 0.04 
(1.16–1.28) 
1.26 ± 0.04 
(1.20–1.34) 
GI 6.13 ± 3.20 (3.60–
17.6) 
4.83 ± 0.76 
(3.53–6.28) 
4.56 ± 0.65 
(3.71–5.93) 
D2cm (%) 54.4 ± 5.8 (47.6–
67.0) 
51.0 ± 3.7 (44.9–
61.3) 
55.2 ± 4.9 (43.7–
64.3) 
GTV  
(n = 20) 
Minimum 
dose (%) 
107.9 ± 3.5 (102.8–
114.4) 
106.5 ± 4.5 
(98.9–115.5) 
114.6 ± 3.3 
(106.8–120.9) 
Maximum 
dose (%) 
121.1 ± 2.9 (114.8–
125.5) 
118.8 ± 3.9 
(113.4–128.1) 
126.1 ± 4.2 
(120–134.1) 
Mean dose 
(%) 
114.3 ± 2.1 (111.5–
119.2) 
113.0 ± 3.6 
(107.8–122.6) 
120.4 ± 4.9 
(106.9–130.3) 
 
Figure 5.2 demonstrates the pairwise differences for the OAR doses for m-RESIST 
and a-RESIST plans with respect to clinical VMAT plans. The average difference between 
clinical VMAT and m-RESIST for all maximum and volumetric OAR doses is a positive 
value, suggesting that in all cases the doses to OAR were lower using m-RESIST compared 
to clinical VMAT plans. In comparison, the majority of the average differences between 
clinical VMAT and a-RESIST were positive values. However, the average difference for 
0.03 cc and 0.35 cc of spinal cord and 5 cc of esophagus were all negative values, at -0.7 
Gy, -0.8 Gy and -0.4 Gy, respectively. These small OAR sparing discrepancies (< 1.0 Gy) 
suggest a-RESIST plans were as good as clinical VMAT and m-RESIST plans. 
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Figure 5.2: The pairwise differences between clinical VMAT and a-RESIST plans and 
clinical VMAT and m-RESIST for maximum (left panel) and volumetric (right panel) 
doses to OAR. The stars represent outlier data points. 
 
The average difference between clinical VMAT and m-RESIST for normal lung 
V20Gy, V10Gy and MLD was 0.8 ± 0.9% (0.03–2.9%), 3.1 ± 4.3% (-2.0–13.9%), 0.5 ± 
0.6 Gy (0.01–1.8 Gy), respectively. Corresponding average difference for those variables 
between the clinical VMAT and a-RESIST were 0.8 ± 1.9% (-3.6–3.8%), 3.2 ± 7.0% (-
12.6–16.4%), 0.3 ± 1.3 Gy (-2.9–2.2 Gy), respectively. This data indicates that, in general, 
both m-RESIST and a-RESIST can provide better normal lung sparing compared to 
original clinical VMAT plans. However, occasionally a-RESIST produces plans with more 
lung dose as can be seen by the negative values for V20Gy, V10Gy and MLD. This can be 
attributed to less than ideal isocenter placement and more intermediate dose-spillage 
associated with the KBP model for VMAT optimization. An example of isocenter 
placement and beam geometry used by all 3 planning approaches can be seen in Figure 
5.3 (unilateral lung lesions). For the clinical VMAT plan, the isocenter placement is 
between the lesions and was planned with coplanar geometry. The yellow box around the 
lesions represents the jaw size to cover both lesions. This larger field size is due to treating 
both lesions at the same time, and although the jaw tracking was enabled, the jaws must 
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track both lesions at once to allow to MLC travel between the lesions. For both a-RESIST 
and m-RESIST, the jaw tracking can be utilized more effectively, which can be seen by the 
small jaw sizes (i. e., jaw tracking locally around each target, one at a time). The upper 
limit for the dose color wash is much higher for the a-RESIST plan at 67 Gy compared to 
60 Gy for m-RESIST and 62.4 Gy for clinical VMAT. This is due to the higher GTV 
maximum dose obtained with a-RESIST planning approach. A higher GTV maximum dose 
is clinically desirable for lung SBRT as long as low doses to normal tissues are maintained. 
The dose color wash in the axial plane of a different patient is demonstrated in Figure 5.4 
(bilateral lung lesions). For this patient, comparable dose distribution can be seen for all 
three plans. However, both m-RESIST and a-RESIST exhibited higher dose to GTVs. For 
the a-RESIST plan, higher intermediate dose spillage can be seen for the posterior lesion.  
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Figure 5.3: Coronal beam geometry and dose color wash for clinical VMAT, m-
RESIST and a-RESIST plans. 
Targets shown are PTVs (orange) and GTVs (red). Rings 2 cm away from the PTVs are in 
purple. OAR shown are skin (purple), heart (blue), ribs (green). The isocenter placement 
at the patient’s midline for both m-RESIST and a-RESIST allow for non-coplanar arc 
geometry, improving planning efficiency and plan quality, escalating tumor dose and 
avoiding potential collisions.  
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Figure 5.4: Dose color wash in the axial plan of a patient with bi-lateral lesions. 
Shown are PTVs (orange), GTVs (red), D2cm ring (purple), ribs (green), heart (blue), 
esophagus (green), cord (yellow), right lung (blue), left lung (pink) and skin (purple). 
Green dot at the viewing plane intersection is the isocenter location. The a-RESIST plan 
provided higher GTV dose and slightly higher intermediate dose spills, which can be seen 
for the posterior lesion but it was within the protocol requirements. 
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5.3.2 Treatment Planning Parameters 
The average total treatment planning time for the a-RESIST script to complete all 
10 lung SBRT patients with two lesions was 12.5 ± 3.5 min (9.1–21.1 min). Time was 
recorded on average 66 min for m-RESIST plans to complete the same tasks as a-RESIST. 
The significant reduction of treatment planning time can be attributed to both the 
automation of arc geometry for a-RESIST as well as the use of the in-house KBP model 
for the VMAT optimization. Specifically, the KBP helped create a clinically acceptable 
and similar plan much quicker than manually inputting and adjusting optimization 
objectives. As can be seen with slightly higher dose to some OAR and inferior CI, PCN, 
HI and D2cm, a-RESIST plans are less desirable, although clinically acceptable and 
protocol compliant, compared to m-RESIST. However, the dramatic treatment planning 
time savings and plan consistency is desirable for a busy clinic. Like m-RESIST plans, a-
RESIST plans allow for additional manual intervention to help improve OAR sparing and 
target coverage with minimal additional treatment planning time.  
 
5.3.3 Treatment Delivery Parameters 
The total number of monitor units for m-RESIST and a-RESIST is about 1.8 times 
higher than for the clinical VMAT plans, as can be seen in Table 5.3. However, due to 
both PTVs being planned separately with separate prescriptions, the average modulation 
factor for the RESIST methods are lower compared to the clinical VMAT method, could 
potentially improve treatment delivery accuracy. The estimated treatment time was 
calculated by adding 10 minutes for initial patient setup, 1 minute to complete a single 
CBCT (two CBCT scans available with RESIST methods) and 3 minutes for tumor 
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matching and applying shifts per CBCT. Although the treatment time is longer for both m-
RESIST and a-RESIST, these treatments can still be delivered during the typical 30-minute 
treatment slot.  
Table 5.3: Comparison of average values of treatment delivery parameters (and 
range) between clinical VMAT, m-RESIST and a-RESIST plans for all 10 lung SBRT 
patients. Mean ± SD (range) was reported. SD = standard deviation. 
Beam delivery 
parameters 
Clinical VMAT m-RESIST a-RESIST 
Total MU per 
fraction 
4020 ± 612 (3091–
5010) 
7272 ± 1136 (5605–
10010) 
7065 ± 605 
(6021–7982) 
Modulation 
factor (MF) 
4.0 ± 0.6 (3.1–5.0) 3.36 ± 0.7 (1.9–5.1) 3.5 ± 0.5 (2.7–
4.9) 
Beam-on time 
(min) 
2.8 ± 0.4 (2.2–3.6) 5.2 ± 0.8 (4.0–7.2) 5.0 ± 0.4 (4.3–
5.7) 
Treatment time 
(min) 
16.8 ± 0.4 (16.2–
17.6) 
23.2 ± 0.8 (22.0–
25.2) 
23.0 ± 0.4 (22.3–
23.7) 
 
5.4 Discussion 
This report describes and assesses the feasibility of the automated RESIST method 
for treating two synchronous lung lesions with SBRT that aims to minimize setup 
uncertainties and significantly improve treatment planning time. The method was validated 
by retroactively planning 10 patients with two lesions who previously underwent VMAT 
SBRT with a single isocenter placed between the two lesions. RESIST consists of a single 
isocenter placed at the patient’s midline and both lesions sharing the isocenter. Unlike 
clinical VMAT, in RESIST plans both lesions have an individual plan which are then 
evaluated with a plan summation. Allowing each lesion to be planned individually allows 
for optimal collimator angles and the best use of the jaw tracking feature to aid in the 
reduction of the normal lung dose. Furthermore, two plans sharing the same isocenter 
allows for more flexibility during patient treatment as demonstrated in Figure 5.5. 
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Figure 5.5: The a-RESIST treatment delivery workflow for single-isocenter/two-
lesion VMAT lung SBRT. 
The physician has the option to line up both tumors on the first daily CBCT and deliver 
both plans (blue box) or match one lesion at a time and treat without entering the room to 
re-setup the patient for the second CBCT (demonstrated on the right side of the flow chart) 
thus improving treatment delivery efficiency and accuracy by reducing the chance of a 
geometric miss. Placement of an isocenter at the mediastinum avoids potential 
patient/gantry collisions, provides greater flexibility of non-coplanar arc geometry and 
eliminates the need for multiple couch movements during CBCT imaging. 
 
Single-isocenter VMAT plans have become a popular treatment option for 
intracranial stereotactic radiosurgery (SRS) and more recently, are becoming of interest for 
extracranial lesions. A few studies have shown the use and feasibility of treating multiple 
lung lesions with a single isocenter approach.22, 23 However, these studies fail to 
acknowledge the treatment planning difficulties or provide solutions to treatment delivery 
uncertainties. The a-RESIST planning method decreases the treatment planning difficulties 
for two lesion lung SBRT plans as well as provides appropriate guidance for more accurate 
treatment delivery, eliminating unwanted stress on the entire SBRT team. Furthermore, to 
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our knowledge, a-RESIST is the first approach to automate single isocenter/multiple lesion 
lung SBRT plans. Automated treatment planning is a fast-developing area of research and, 
with the recent availability of writeable scripting using Varian ESAPI, will continue to gain 
favor. A recent study demonstrated the use of automation in an existing clinical workflow 
and showed the feasibility of automation for improving clinical efficiency and safety for 
total body irradiation (TBI).24 Similar to TBI procedures, lung SBRT procedures are high 
risk, involving large doses. The a-RESIST method can be used to reduce planning errors 
and potentially reduce the chance of tumor misalignment for treatment. Recent publications 
have explored automation of planning for various treatment of other sites25-27 although a-
RESIST is the first of its kind for multiple lesions VMAT lung SBRT treatment. Further 
validation and clinical implementation of a-RESIST method for multi-lesions lung SBRT 
treatment is ongoing. 
Further improvement of a-RESIST is ongoing in our center including improvement 
of the KBP optimization model for two-lesion lung SBRT plans and a more “patient-
specific” approach to isocenter placement. Simulated collision detection is a feature 
available when using Varian HyperArc module for intracranial SRS treatments and has 
been further developed by multiple researchers.28,29,30 However, simulated collision 
detection for extracranial SBRT has yet to be studied and would be the next step to the a-
RESIST method to further ensure an efficient treatment delivery. Efficacy of a-RESIST 
has been demonstrated for two lung lesions and can potentially be used for more than two 
lung lesions as well as other extracranial treatment sites such as multi-lesion liver SBRT 
or oligometastastic abdominal/pelvic lymph nodes SBRT 
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5.5 Conclusion 
Using the a-RESIST planning method for synchronous lung lesions can decrease 
planning time and allow planners to create clinically acceptable lung SBRT treatment 
plans. The RESIST method reduces the chance of a geometric miss due to setup 
uncertainties by allowing for planning and setup of each lesion individually. Furthermore, 
automation of the planning technique will allow for standardized treatment plans while 
allowing user input to further increase the plan quality and treatment efficiency. Utilizing 
an in-house trained lung SBRT RP model helps ensure treatment plans are of consistent 
high quality. Further improvement of the a-RESIST script to ensure more precise isocenter 
location as well as well-trained KBP models for patient-specific multi-targets could further 
improve plan quality, reduce inter-planner variability and inconsistency and improve 
patient safety and clinic workflow. 
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CHAPTER 6. STUDY CONCLUSIONS 
6.1 Study Summary 
This dissertation has described the development of a methodology for treating 
multiple lung lesions efficiently and accurately with single-isocenter VMAT SBRT. 
Beginning in Chapter 1, a brief history of SBRT is presented followed by a discussion of 
synchronous multiple lesion treatments and the current clinical limitations. Chapter 1 is 
concluded with a presentation of the dissertation outline and the major clinical innovations 
presented in each chapter.  
Chapter 2 presented a dosimetric study of two common treatment planning 
methods for multiple lesion lung VMAT SBRT. The first technique consists of two plans 
and two different isocenters, one for each lesion. The isocenter is placed in the center of 
the lesion. The second technique plans for both lesions at the same time using a single-
isocenter VMAT SBRT plan. The isocenter is placed approximately between the two 
lesions. This study validated the hypothesis that the single-isocenter plans would be 
dosimetrically equivalent to the multi-isocenter and would provide more efficient 
treatments. Treating both lesions with a single isocenter reduced the beam-on time by a 
factor of 1.5, thus improving patient convenience. Efficient treatments can help ensure the 
patient remains in the ideal treatment position while releasing the treatment machine to be 
used for more patient treatments. However, there was no evidence that the single isocenter 
plans were more accurate upon patient setup and delivery. Small setup errors were 
observed upon evaluation of the pre-treatment CBCTs of patients previously treated with 
a single-isocenter VMAT SBRT plan. Unfortunately, there is no method available in 
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Eclipse TPS to quantitate the dosimetric effects of these setup errors on targets or 
uninvolved structures.  
For the study in Chapter 3 a novel transformation method was created to more 
accurately simulate the dosimetric impact of patient setup errors. This method was used to 
quantitate the effect of possible small setup errors in dose distribution of the treatment of 
multiple lesion VMAT SBRT using a single isocenter. This method produced random 
translations and rotations on the patient CT, similar to the observable patient setup errors, 
in order for a dose calculation to be performed, per treatment fraction. This study validated 
the hypothesis that small patient setup errors could lead to clinically unacceptable target 
coverage loss. Using this method, the study demonstrated that the largest risk of target dose 
coverage loss of up to 72% was observed for the smallest lesion volumes. Likewise, it was 
determined that a loss in optimal BED was possible for many targets, potentially 
compromising tumor local control.  
Before completion of this study, a linear relationship between target coverage loss 
and target distance to isocenter was expected, as shown by multiple sources in the treatment 
of multi-lesion brain SRS.1,2 However, in this cohort, upon analyzing the target coverage 
data, no clear relationship was found. This is likely due to multiple confounding factors 
including the drastic change in tissue densities in the thorax, the large variability in lung 
tumor sizes and lung tumor locations. For lung lesions, small rotations and translations will 
lead to larger changes in source to surface distance (SSD) than for lesions of the brain due 
to the oval shape of the thorax in comparison to the spherical shape of the brain. Likewise, 
small rotation and translations may result in more or less of the beam going through dense 
structures like the ribs, potentially resulting in a large dosimetric change to both targets and 
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normal tissues. The previous brain SRS studies calculated coverage loss based on one 
simulation of the dose distribution. In contrast, our study simulated a different 
transformation for each treatment fraction. The method used in Chapter 3 likely produced 
a more accurate representation of target coverage loss for multiple fraction treatments. 
To create a more accurate treatment alternative for these patients, the Restricted 
Single-Isocenter Stereotactic Body Radiotherapy (RESIST) method was created and 
described in Chapter 4. RESIST utilizes a simplified approach by placing a single-
isocenter at the mediastinum. It uses partial arcs to minimize dose to the other lung. It 
allows for an individual plan to be created for each tumor, using the first plan as the base-
dose for the second plan, while still allowing both tumors to be treated in the same session. 
The technique uses novel features in Eclipse TPS to provide better target dose conformity 
and gradient indices and lower doses to adjacent normal structures when compared to the 
single-isocenter VMAT treatment described in Chapter 2. Using RESIST to treat 
synchronous lung lesions with VMAT SBRT significantly reduces plan complexity, as 
demonstrated by smaller beam modulation factors, without unreasonably increasing 
treatment time. RESIST reduces the chance of a geometric miss due by allowing CBCT 
matching of one tumor at a time. Placement of isocenter at the mediastinum avoids 
potential patient/linac gantry collisions, provides greater flexibility of non-coplanar arcs 
and eliminates the need for multiple couch movements during CBCT imaging, thus 
reducing the number of times a therapist must enter the treatment room.  
Automation of the RESIST method is presented in Chapter 5. This automated 
RESIST (a-RESIST) method is the first automated treatment planning method for 
synchronous multiple lung lesion VMAT SBRT. This study validated the hypothesis that 
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a-RESIST would produce acceptable treatment plans quicker and more consistently than 
manually created plans. Not only does the automation significantly reduce the treatment 
planning time, from over 1 hour to about 20 minutes, it can reduce treatment planning 
errors and is adaptable to fit the preferences of the physician. The a-RESIST method 
automatically sets isocenter, creates partial arc beam geometry, choses appropriate dose 
calculation algorithms, and performs VMAT optimization using an in-house trained 
knowledge-based planning model for lung SBRT. The a-RESIST method provides 
guidance for inexperienced planners by standardizing beam geometry and plan 
optimization using DVH estimates. It produces clinically acceptable two lesion VMAT 
lung SBRT plans efficiently.  
Following the guidance presented in this dissertation, treatment planners with 
minimal experience in multi-lesion lung SBRT will be able to produce efficient and 
accurate treatment plans. The methods presented are adaptable and are a proof-of-concept 
that these complicated treatment plans can not only be created more resourcefully and 
consistently, but can be automated with the clinic’s aims in mind. 
 
6.2 Study Limitations and Future Perspectives 
This study aimed to create a protocol for the safe, effective, accurate and efficient 
treatment of multiple lung lesions with VMAT SBRT. Although there is confidence this 
dissertation will improve these complicated treatments, the study is not without limitations. 
In all chapters, the statistical analysis is limited by the number of patients. Patient number 
was chosen based on the cohort available in the clinic at The University of Kentucky, and 
therefore will affect the study power. Nevertheless, these studies are important and provide 
the groundwork for potential larger studies that could involve more patient data. 
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Due to the novelty of this study, patient follow up is needed to support the 
conclusions made in a few of the chapters. In Chapter 2, two treatment planning 
techniques are described and determined to be dosimetrically equivalent. However, further 
follow up of clinically treated patients is warranted to determine if the dosimetric 
equivalency translates to equivalent local control. Furthermore, Chapter 3 suggests that 
the small setup errors observed in the pre-treatment imaging of patients treated with single-
isocenter VMAT SBRT will result in dose coverage loss that may impact the local control 
of the lesions. So far, The University of Kentucky Radiation Oncology clinic has used this 
treatment technique on approximately 30 patients with two synchronous lung lesions each 
in the last 2 years and further follow up of these patients is needed to determine if the 
observed setup errors resulted in inferior rates of local control. Early follow up results of 
14 patients (mean, 9 months) showed high local control rates (100%)3, however longer 
follow up is needed to determine overall survival and future local control. For these 
patients, the conclusion was made that dose coverage loss is magnified in smaller lesions, 
however, due to the complicated relationships between tumor location, tumor size, and 
heterogeneous densities in lung treatments no definitive relationship can be determined 
regarding tumor size and coverage loss. 
In Chapter 3, a novel technique for the simulation of patient setup errors in Eclipse 
TPS is presented. In the current version, the script integrates with the Image Registration 
module in Eclipse TPS. Thus, this method is currently only available to users with Eclipse 
TPS. Although this TPS is widely used, a different method may need to be created for 
alternative TPS.  
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Chapter 4 describes the RESIST method for treating synchronous multiple lung 
lesions utilizing novel features available in the Eclipse TPS (version 15.5), such as aperture 
shape controller. These features will not be available to all users with previous versions; 
thus, adaptation may be necessary when trying to implement this method. The RESIST 
method has been used to treat three patients. This method can continue to be used for 
multiple lesion SBRT and clinical follow-up can be performed to determine the advantages 
in overall survival and local control rates, if any. Furthermore, the a-RESIST method in 
Chapter 5 is restricted to users with the Eclipse TPS (version 15.5). Although a-RESIST 
provides acceptable treatment plans, they are slightly inferior to manually created plans. 
Further refinement of the automation could provide more optimal and patient specific 
isocenter placement. Currently, the knowledge-based planning (KBP) approach with dose 
volume histogram (DVH) estimates via RapidPlan (RP) model used in a-RESIST was 
trained using single-isocenter/single-lesion lung SBRT plans. Although the dose to each 
lesion is optimized individually, the plans are evaluated in a plan summation containing 
plans to both lesions. The KBP approach does not take this into account during 
optimization resulting in an inferior plan. A model trained on single-isocenter/two-lesion 
plans could further improve the plan quality of a-RESIST.  
The isocenter location in a-RESIST is chosen at patient midline to reduce the 
chance of a patient collision while the linac gantry rotates around the patient. However, 
there is no way to ensure patient safety without a “dry-run” of the treatment before delivery. 
This may increase the time the patient must remain on the table and there is currently no 
way to simulate this in the TPS. The development and implementation of a simulated 
collision detection module in Eclipse TPS for extracranial lesions could further improve a-
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RESIST and could be used for lesions in other sites. Fully integrating and automating the 
RESIST method with the TPS could further improve the technique. 
As an expansion of this thesis, a grant proposal has been accepted and funded (at 
Varian Medical Systems, Palo Alto CA) regarding the treatment of synchronous multiple 
extracranial lesions with SBRT on the recently introduced Varian Halcyon Linac.4 The 
Halcyon linac has a single 6MV-FFF beam and allows for quick gantry rotations with fast 
dual-stacked and staggered MLCs, but does not allow for non-coplanar beam geometry. 
Currently, the Halcyon can only correct translational set up errors for patient set up and 
verification. Therefore, there is a tremendous interest on quantifying the dosimetric effects 
of rotational setup uncertainties and developing a novel approach to minimize those errors 
for multiple lesions on Halcyon, analogous to the novel technique used to quantify those 
previously treated on the Varian Truebeam and discussed in this dissertation. 
 Further expanding on RESIST, studies can be performed about the efficacy of the 
method on different machines, such as the Varian Halcyon. Likewise, RESIST can be 
expanded to other treatment sites including the liver and for multi-site/multi-lesion SBRT. 
Utilizing the RESIST approach to minimize dose to normal brain and improve localization 
accuracy in the treatment of multiple brain lesions for linac-bases SRS in another avenue 
of research. Exploration of RESIST’s potential to escalate dose to large tumors with 
simultaneous integrated boost while sparing normal tissues could prove to be a useful 
treatment option and merits future investigation.  
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APPENDICES 
APPENDIX 1. GLOSSARY 
6DOF six-degrees-of-freedom 
ACR American College of Radiology  
a-RESIST Automated Restricted Single-Isocenter Stereotactic 
Body Radiotherapy 
ASTRO American Society for Therapeutic Radiology and 
Oncology 
BED Biological Effective Dose 
BOT Beam on time 
CBCT Cone Beam Computed Tomography  
CGS Calculation Grid Size 
CI Conformity Index 
CN Conformation Number 
D Dose 
DCA Dynamic Conformal Arc 
DTA Distance to Agreement 
DVH Dose Volume Histogram 
ESAPI Eclipse Scripting Application Programming 
Interface 
ESR Extracranial Stereotactic Radioablation 
FFF Flattening Filter Free 
GD Gradient Distance 
GI Gradient Index 
GTV Gross Tumor Volume 
HI  Heterogeneity Index 
IMRT Intensity Modulated Radiation Therapy 
ITV Internal Target Volume 
KBP Knowledge-based planning  
LLL Left Lower Lobe 
LUL Left Upper Lobe 
MF Modulation Factor 
MIP Maximum Intensity Projection 
MLC Multi-leaf Collimator 
MLD Mean Lung Dose 
m-RESIST Manual Restricted Single-Isocenter Stereotactic 
Body Radiotherapy 
MU Monitor Units 
NSCLC Non-Small Cell Lung Cancer 
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NTO Normal Tissue Objective 
OAR Organ at Risk 
PIV Prescription Isodose Volume 
PO Photon Optimizer 
PTV Planning Target Volume 
QA Quality Assurance 
RESIST Restricted Single-Isocenter Stereotactic Body 
Radiotherapy  
RLL Right Lower Lobe 
RP RapidPlan 
RTOG Radiation Therapy Oncology Group 
RUL Right Upper Lobe 
SBRT Stereotactic Body Radiation Therapy 
SRS Stereotactic Radiosurgery  
SSD Source to Surface Distance 
STD Standard Deviation 
TPS Treatment Planning System 
TV Target Volume 
V Volume 
VMAT Volumetric Modulated Arc Therapy  
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APPENDIX 2. MATLAB SCRIPT FOR SIMULATION OF RANDOM SETUP 
ERRORS 
%Before starting, replace the current registration file with whatever 
%patient you are working with. Change the number of fractions to correspond 
%with the current patient. 
 
fractionnumber=1; 
while fractionnumber<6 
 
% thetax, thetay and thetaz represent the random rotations between -2 and 2 
% degrees.  
 
thetax=rand*4-2; 
thetay=rand*4-2; 
thetaz=rand*4-2; 
 
%Rotx, roty and rotz are the three rotation matrices. 
 
rotx=[1,0,0,0;0,cosd(thetax),sind(thetax),0;0,sind(thetax),cosd(thetax),0;0,0,0,1]; 
roty=[cosd(thetay),0,sind(thetay),0;0,1,0,0;sind(thetay),0,cosd(thetay),0;0,0,0,1]; 
rotz=[cosd(thetaz),sind(thetaz),0,0;sind(thetaz),cosd(thetaz),0,0;0,0,1,0;0,0,0,1]; 
 
%Multiplying the matrices together will get my rotation matrix in 3D. 
 
rotationmatrix=rotx*roty*rotz; 
 
%x, y and z are the random translation between -5mm and 5mm 
 
x=rand*10-5; 
y=rand*10-5; 
z=rand*10-5; 
translationmatrix=[1,0,0,x;0,1,0,y;0,0,1,z;0,0,0,1]; 
 
%Multiplying the rotationmatrix and the translation matrix will get the 
%transformation matrix needed for the RE DICOM file 
 
transformationmatrix=rotationmatrix*translationmatrix; 
transformationmatrix=transpose(transformationmatrix); 
newtransformationmatrix=reshape(transformationmatrix,16,1); 
 
%Replacing the current DICOM transformation matrix with my new randomly 
%generated transformation matrix and saving the DICOM file under the 
%specified name 
 
info=dicominfo(''); 
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read=dicomread(''); 
t=newtransformationmatrix; 
info.RegistrationSequence.Item_2.MatrixRegistrationSequence.Item_1.MatrixSequence.I
tem_1.FrameOfReferenceTransformationMatrix=t; 
basename='fraction'; 
name=[basename,num2str(fractionnumber)]; 
dicomwrite(read,name,info, 'CreateMode', 'copy'); 
fractionnumber=fractionnumber+1; 
end
 
 
APPENDIX 3. ESAPI SCRIPT FOR a-RESIST 
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